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ABSTRACT
OBJECTIVES
The objectives of this study are to: 1) assess construct validity of the World Health
Organization’s Quality of Life-BREF (WHOQOL-BREF) instrument, 2) evaluate quality of life
(QOL) among adults with autism and 3) assess the prevalence, healthcare utilization and costs,
and medication use among adults with autism enrolled in the Medicaid program.
METHODS
The study methodology included both primary and secondary data collection techniques. For
objectives one and two, a cross-sectional, descriptive quantitative design was utilized. An
internet-based survey using Qualtrics was administered to adults with autism enrolled with the
Interactive Autism Network (IAN). The WHOQOL-BREF instrument was validated using
confirmatory factor analysis (CFA). Structural equation modeling (SEM) was used to identify
the factors influencing QOL among adults with autism. For objective three, a retrospective
descriptive analysis of 2006-2008 Medicaid claims data for 39 states was conducted. Logistic
regression was performed to assess trends in prevalence of autism and generalized linear mixed
models (GLMM) were used to determine the predictors of healthcare utilization and costs among
adults with autism.
RESULTS
The survey sample included 265 adults with autism. Based on the CFA analysis for objective
one, the second-order hierarchical model of WHOQOL-BREF instrument was considered the
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best fitting model among adults with autism. Results from the SEM analysis conducted under
objective two revealed the modified Wilson and Cleary’s QOL model tested in the study to have
an adequate fit. Study results depicted autism severity (negative), maladaptive coping
(negative), social support (positive) and functional independence (positive) as significant
predictors of QOL. Study analyses under objective three highlighted a ~38% increase in the
prevalence of autism from 2006 to 2008. Significant variation between demographic variables
and healthcare expenditure and costs was observed after controlling for disease severity and
other comorbid conditions.
CONCLUSIONS
Study results indicated that the WHOQOL-BREF is a psychometrically sound instrument to
assess quality of life among adults with autism. Health care professionals involved in the
management of autism among these adults should consider factors such as social support and
coping when designing treatment strategies. With increasing prevalence, medical services as
well as costs associated with management of adults with autism enrolled in the Medicaid
program are likely to increase in the coming years.
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CHAPTER 1
INTRODUCTION
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Autism spectrum disorders
Overview of autism
Autism spectrum disorders are neurodevelopmental disorders that are associated with significant
impairment of social interaction and communication, and restricted and repetitive behavior
(American Psychiatric Association, 2000). There are three types of autism: autistic disorder
(also known as “classic” autism), Asperger syndrome and pervasive developmental disorder –
not otherwise specified (PDD-NOS; known as “atypical autism”). Autistic disorder is the most
severe form of autism, while Asperger syndrome and PDD-NOS are the milder forms of autism
(CDC Website, 2015).
Etiology of autism
Genetic and environmental factors are believed to play a major role in the occurrence of autism
(Newschaffer et al., 2007). The link between environmental exposures and autism is also
plausible via gene-environment complex interaction; however, more research is currently being
conducted to identify specific exposures associated with autism. Other potential risk factors and
biomarkers of autism include infection and immune dysfunction, neurotransmitter, peptides and
growth factors, endocrine factors, obstetric factors, xenobiotic factors, prescription medications
(such as thalidomide, valproic acid, misoprostol), metals and other environmental exposures
(Newschaffer, et al., 2007).
Prevalence of autism in adults
Although autism was initially considered a rare disorder affecting mainly children, evidence
suggests that it is a lifelong disorder and it is a more common disorder than previously
considered (Brugha et al., 2011; Newschaffer, et al., 2007). Prevalence of autism among
children has significantly increased in the United States (US) in the past few decades (Boyle et
2

al., 2011). Possible reasons for rise in the prevalence rate are changes in screening and
diagnostic criteria, increased awareness and knowledge among parents, healthcare professionals
and society, and true increase in the prevalence rates (Wing & Potter, 2002). Currently, about 1
in 68 children have autism in the US (MMWR, 2014). Epidemiological data of adults with
autism in the US is limited. One study has estimated the prevalence rate among adults with
autism in England (Brugha, et al., 2011). Results from the study suggest that prevalence of
autism in adults is similar to that in children (~1%). Prevalence rates were higher in males than
females (Brugha, et al., 2011).
Healthcare utilization and costs associated with autism among adults
Past studies have highlighted a significant healthcare cost burden associated with autism. In a
study of 2003 MarketScan data, Shimabukaro et al. (2007) reported a $4,690 incremental cost
(~4 times higher) per year among privately insured individuals with autism aged 18-21 years
compared to those without autism. The authors found that adolescent and children with autism
incurred ~8-9.5 times greater median healthcare expenditure compared to children without the
disorder. In their analysis of Mississippi Medicaid data, Khanna et al. (2013) fount that state
Medicaid spent about $2 million for psychotropic drug costs among individuals with autism in
2007. Adults with autism were found to have the highest number of prescription claims with
$3,391 average drug cost per recipient. In terms of hospitalization burden in the US, there were
~8,200 hospitalizations among adults with autism (>21 years) in 2007 (Lokhandwala, Khanna, &
West-Strum, 2011). Past estimates suggest that the lifetime incremental societal direct and
indirect cost of autism is $3.2 million where adult care (21%) and lost productivity (59.3%)
account for the highest components of the total cost (Ganz, 2007). Based on recent estimates,
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the direct and indirect economic burden of autism is ~$137 billion per year in the US (Autism
Speaks 1, 2012).
Treatment of autism
Early diagnosis and treatment can help improve outcomes among individuals with autism. There
are medical as well as nonmedical interventions and treatment options for individuals with
autism beyond childhood. In general, the treatment options can be classified into behavioral
therapies, pharmacological medicine, dietary approaches and complementary and alternative
medicines (CDC Website, 2015). Interventions for adults with autism are mainly focused on
providing better employment and living arrangements. For adolescents, apart from employment
and living arrangements, additional training on vocational skills is provided (Volkmar, Cook,
Pomeroy, Realmuto, & Tanguay, 1999). Currently, there is a lack of published literature on
successful behavioral therapies among adults with autism (IAN Website, 2008). Most of the
studies are restricted to children or young adolescent with autism. Based on the recently
published meta-analysis of psychosocial interventions in adults with autism, only three types of
interventions are studied in adults with autism (Bishop-Fitzpatrick, Minshew, & Eack, 2013).
They include social cognition training, Applied Behavioral Analysis (ABA), and small
community-based programs. ABA brings meaningful changes in behavior in terms of
communication, social behavior, self-care, school and employment (CDC Website, 2015).
Several studies confirm affirmative changes due to ABA in terms of employment and education
in adolescent and young children with autism (Autims Speaks 2, 2015; IMPAQ International,
2010; Kasari & Lawton, 2010). There are several computer-based interventions available for
adults with autism to address social deficits and communication (Bishop-Fitzpatrick, et al.,
2013). In general, adults with autism with higher cognitive capabilities have seen better
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improvements in employment and independent living due to the interventions (Volkmar, et al.,
1999).
Currently there are no drugs available to cure autism. Pharmacotherapy is increasingly
becoming the treatment mainstay. Antipsychotics such as risperidone and aripripazole are
approved by the US Food and Drug Administration to treat severe tantrums, aggression and selfinjurious behavior among children and adolescents with autism. Safety and efficacy of these
agents are yet to be established in the adult population. It is unclear if the pharmacological
treatments results among children can be generalized to adults with autism. A recent case series
of adults with autism treated with aripriprazole may have had positive benefits in some patients
(Jordan, Robertson, Catani, Craig, & Murphy, 2012). In the last few decades, there is an
increase in off-label psychotropic medication use among individuals with autism, (Esbensen,
Greenberg, Seltzer, & Aman, 2009; R. Khanna, et al., 2013) including adults. Complementary
and alternative medicine (CAM) approaches are also becoming common among individuals with
autism. However, there is a lack of well-documented benefit and safety profile of CAM among
individuals with autism.
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The concept of quality of life and health-related quality of life
Quality of life (QOL) is increasingly becoming an important treatment outcome in clinical trials,
health care intervention and treatment, health surveys and epidemiological studies. Although
many studies have used health-related quality of life (HRQOL) and QOL interchangeably, they
are indeed very different concepts (Apolone & Mosconi, 1998; Feldman, Grundland,
McCullough, & Wright, 2000; Patrick & Deyo, 1989). The World Health Organization defines
QOL as "an individual's perception of their position in life in the context of the culture and value
systems in which they live and in relation to their goals, expectations, standards and concerns.”
(WHOQoL Group, 1993). It is a broad construct that reflects an individual’s physical,
psychological, and social health, and its relationship with the environment. It encompasses
health and non-health related domains including family life, environment, financing, housing,
and other aspects of life. HRQOL, like subjective health status, is a part of overall QOL which
reflects perceived health and well-being of an individual. HRQOL is referred to “the measure of
the patients’ functioning, well-being and general health perception in each of three domains:
physical, psychological and social” (Apolone & Mosconi, 1998).
Types of quality of life measures
A good QOL measure should have a good discriminative power to differentiate between
individuals with better and worse health (Guyatt, Feeny, & Patrick, 1993). Therefore, it is often
suggested to test the validity, reliability, and responsiveness of generic or disease-specific
instruments in the same (Patrick & Deyo, 1989) as well as different populations. There are two
most common approaches to classify the QOL measures: generic measures and disease-specific
(or condition-specific) measures (Dowie et al., 1998; Guyatt, et al., 1993; Patrick & Deyo, 1989).
A key advantage of generic measures is that they are more general in nature and are broadly
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applied to different disease states and conditions. However, they are often criticized as less
“sensitive” and “responsive” to a specific disease state and hence often miss small but important
changes in health (Guyatt, et al., 1993). Instead, disease-specific measures are more specific to
the disease state (e.g., back pain or diabetes), certain function (sleep or emotional function) or
special population (older adults or children with disability). They are often more responsive and
clinically important to measure a specific aspect of the QOL in a particular patient. Generic
measures are more often used because they allow comparison of different interventions and
disease states (Patrick & Deyo, 1989). This information is useful for policy makers and other
health care professionals to make important decisions, particularly in terms of resource
allocation.
Generic instruments
Generic instruments include health profiles (36-item Short Form Health Survey, 12-item short
form health survey version 2.0, sickness impact profiles, WHOQOL-BREF, etc.) and utility
measures (EuroQol-5D, Health Utilities Index [HUI], Short Form-6 dimension [SF-6D], etc.).
Health profiles usually measure all the aspects of health and are used across different
demographics, irrespective of the disease state. Utility measures (also known as preferencebased measures) mainly assess individuals’ desire or preference for the condition or an outcome
(Guyatt, et al., 1993; Torrance, 1987). Utility measures are derived from the modern utility
theory and decision theory. A major advantage of utility measures is that they provide a utility
score which is a single number on a continuum between 0.0 (death) and 1.0 (perfect health).
Utilities form an underlying component in the assessment of quality-adjusted life-years
(QALYs), which is often used in economic analysis to justify resources allocated to a particular
treatment (Guyatt, et al., 1993; Torrance, 1987).
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Quality of life among adults with autism
In recent years, QOL has emerged as a key outcome criterion to understand the physical and
psychological impact of a disorder on an individual’s well-being. Burgess and Gutstein (2007)
suggested that studies should include social support, academic success, employment, and selfdetermination as key predictors of quality of life among adults with autism. However, to date,
only a handful of studies have examined HRQOL or QOL among adults with autism. Majority
of the studies have reported lower HRQOL or QOL among adults with autism (Billstedt,
Gillberg, & Gillberg, 2011; Eaves & Ho, 2008; Jennes-Coussens, Magill-Evans, & Koning,
2006; Kamio, Inada, & Koyama, 2013; Kamp-Becker, Schroder, Remschmidt, & Bachmann,
2010; Rahul Khanna, Jariwala-Parikh, West-Strum, & Mahabaleshwarkar, 2014; Renty &
Roeyers, 2006). Two studies have reported better QOL among adults with autism enrolled in
behavioral treatment programs (Gerber, Baud, Giroud, & Galli Carminati, 2008; Persson, 2000).
According to a study by Renty and Roeyers, (2006) perceived informal social support
was found to be a significant predictor of QOL among adults with high-functioning autism
(HFA). However, the authors found no relationship between QOL and received informal and
formal social support. Another study conducted by Kamp-Becker et al. (2010) reported lower
HRQOL among adolescents and adults with HFA than the general population. Jennes-Coussens
et al. (2006) also reported lower QOL, particularly physical and social domains, among patients
with Asperger syndrome.
The most recent study conducted by Kamio et al. (2013) utilized a nationwide survey to
assess predictors of QOL among adults with HFA. They reported lower psychosocial QOL
among adults with HFA compared to general Japanese adults. Mothers’ support and early
diagnosis of the disease were associated with better QOL among adults. Aggressive behavior
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was related to lower quality of life among adults. Two studies compared QOL among adults
with autism to a disease reference group (Cottenceau et al., 2012; Kamp-Becker, et al., 2010).
The results indicated that adults with autism have better QOL compared to schizophrenia
patients (Kamp-Becker, et al., 2010), while another study found lower QOL compared to
diabetes patients (Cottenceau, et al., 2012).
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Study need
I.

Need to test the psychometric properties of the health status instrument among adults
with autism

There are two most common approaches to classify QOL instruments: generic instruments and
disease-specific (or condition-specific) instruments (Dowie, et al., 1998; Guyatt, et al., 1993;
Patrick & Deyo, 1989). Generic instruments are used to compare self-reported health status
across different groups and disease conditions. Occasionally, the instruments are not reliable in
certain subgroups such as elderly, low income, educated, different ethnic and cultural people.
Therefore, in order to make the interpretation and comparison better, it is recommended that
factorial validity and reliability of the instruments should be determined in different samples
(Reed, 1998). Although past studies have used different QOL and HRQOL instruments to assess
health status among adults with autism, none of the studies have tested the psychometric
properties of the instruments.
Chapter 2 addresses the gap in literature by testing the psychometric properties of
WHOQOL-BREF instrument among adults with autism. The WHOQOL-BREF instrument was
initially developed to compare health status among individuals with different disease as well as
different cultural origins (WHOQoL Group, 1993). Specifically, construct validity of the
WHOQOL-BREF instrument was tested through confirmatory factor analysis and hypothesis
testing. In addition, reliability and floor and ceiling effect of the WHOQOL-BREF instrument
data is presented.

II.

Need to evaluate quality of life (QOL) among adults with autism
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As previously stated, autism is a developmental disorder that persists into adulthood (Brugha, et
al., 2011; Newschaffer, et al., 2007). Despite an increasing amount of literature on predictors of
outcomes in children with autism and their caregivers, very little is known about the outcomes in
adults with autism. In addition, increase in the prevalence in adults with autism could impose
significant humanistic and economic burden on the healthcare system (Piven & Rabins, 2011).
One of the longest and largest prospective studies of a community sample of individuals with
autism followed from childhood through adulthood reported worst psychosocial outcomes
among adults with autism (Billstedt, Gillberg, & Gillberg, 2005).
Chapter 3 tests the relationship between autism severity, coping, functional
independence, social support and quality of life in adults with autism. This study utilizes Wilson
and Cleary’s (1995) QOL model as a guiding framework. Certain modifications were made to
Wilson and Cleary’s QOL model to accommodate key constructs such as social support and
coping that are essential in the context of the study. A cross-sectional descriptive design is used
by conducting an online survey of these adults using the Qualtrics software program. Adults
with autism registered with the Interactive Autism Network (IAN) were approached for the
purpose of the study.

III.

Need to assess autism prevalence, healthcare utilization and costs, and medication use
among adults with autism enrolled in Medicaid.

With an increase in prevalence, there is an increase in the demand to support individuals with
autism throughout their lifespan. It is essential to understand if adults with autism are receiving
appropriate healthcare services. A study surveying physicians reported that physicians have not
received adequate training to provide medical care to adults with autism (Bruder, Kerins,
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Mazzarella, Sims, & Stein, 2012). Limited literature currently exists detailing autism-related
utilization and costs for medical services and prescription drugs in adult population, particularly
Medicaid beneficiaries. In addition, assessing the demographic variation in prevalence,
incidence, costs, and resource utilization among adults with autism enrolled in Medicaid can help
identify the need for targeting interventions in the US. For that purpose, in chapter 4, a
retrospective analysis of the 2006-2008 Medicaid administrative claims data is conducted.
Specifically, the trends in prevalence and medical services and prescription use were assessed.
In addition, the predictors of healthcare utilization and costs among adults with autism in
Medicaid are studied.

12

Specific aims and objectives
1. To test the psychometric properties of QOL instrument among adults with autism.
a.

Assess construct validity of the WHOQOL-BREF instrument.

b.

Assess the reliability and floor and ceiling effect of the WHOQOL BREF instrument.

2. To evaluate QOL among adults with autism.
a.

Determine QOL among adults with autism in the United States.

b.

Identify the determinants of QOL among adults with autism by using a modified
version of the Wilson and Cleary’s QOL conceptual model to study the relationship
between autism severity, coping, functional independence, social support and quality
of life in adults with autism.

3. To study the prevalence, healthcare utilization and costs, and medication use among adults
with autism enrolled in the Medicaid program (national data).
a.

Estimate the trends in i) autism prevalence and ii) autism-related medical services and
prescription use.

b.

Assess the predictors of healthcare utilization and costs among adults with autism in
Medicaid.

13
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CHAPTER 2
PSYCHOMETRIC PROPERTIES OF WHOQOL-BREF INSTRUMENT AMONG
ADULTS WITH AUTISM
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INTRODUCTION
Autism spectrum disorders are neurodevelopmental disorders that are associated with limited
social development, behavioral and language skills. Over the last few decades, there has been a
substantial increase in the prevalence rate of autism in the United Stated (US) (CDC Website,
2015). Current estimates suggest that 1 in every 68 (~1.47%) children in the US has autism
(MMWR, 2014). Prevalence rate of autism among adults is currently unknown in the US;
however, based on the study conducted in England, the rate among adults has been found to be
similar to those among children (~1%; Bruga et al., 2011).
Quality of life (QOL) signifies an individual’s perception of their position in life and the
role of culture and value systems in influencing those perceptions. Besides including health
(physical, psychological, and social) related domains, QOL also encompasses non-health
(political, environmental) related domains (WHOQoL Group, 1993). There are several generic
and disease-specific instruments available to measure QOL. The merit of the use of generic
instrument is the ability to compare QOL among different population and disease condition
(Guyatt, Feeny, & Patrick, 1993). The World Health Organization’s Quality of Life-100
(WHOQOL-100), developed by World Health Organization (WHO), is the most commonly and
widely used generic QOL instrument. This generic instrument has more than 20 international
versions and cross-cultural adaptations making it convenient to compare patients with different
disease conditions and different cultures. In order to reduce respondent burden, WHOQOLBREF, an abbreviated version of the WHOQOL-100 instrument was developed (Skevington,
Lotfy, & O'Connell, 2004). WHOQOL-BREF contains 26-items including one item on the 24
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facets of QOL, one item assessing overall QOL, and one item assessing general health. The 24items are measured on a five-point scale. Four broad domains consist of: physical health (seven
items), psychological health (six items), social relationships (three items) and environment (eight
items).
Results from the first international field trial conducted in 23 countries (n=11,830)
indicated that the WHOQOL-BREF had excellent to good validity and reliability (Skevington, et
al., 2004). The instrument has been validated among general population in different countries
including US (Colbourn, Masache, & Skordis-Worrall, 2012; Hanestad, Rustoen, Knudsen,
Lerdal, & Wahl, 2004; Jaracz, Kalfoss, Gorna, & Baczyk, 2006; Li, Kay, & Nokkaew, 2008;
Nedjat, Montazeri, Holakouie, Mohammad, & Majdzadeh, 2008; Usefy et al., 2010; Xia, Li,
Hau, Liu, & Lu, 2012; Yao, Chung, Yu, & Wang, 2002) as well as diseased population such as
pulmonary tuberculosis, disability students, physical impairments traumatic brain injury,
depression, traumatic spinal-cord injury, psychiatric adult population, rheumatoid arthritis and
others (Bandar, Jani, & Karim, 2014; Berlim, Pavanello, Caldieraro, & Fleck, 2005; Chiu et al.,
2006; Chung, Lan, & Yang, 2012; Jang, Hsieh, Wang, & Wu, 2004; Kim, Hahn, Im, & Yang,
2013; Masthoff, Trompenaars, Van Heck, Hodiamont, & De Vries, 2005; Miller, Chan, Ferrin,
Lin, & Chan, 2008; W. J. Taylor, Myers, Simpson, McPherson, & Weatherall, 2004;
Trompenaars, Masthoff, Van Heck, Hodiamont, & De Vries, 2005). The results of these past
studies suggest that the WHOQOL-BREF instrument possesses good psychometric properties.
The four-factor hierarchical model, where second-order factor (QOL) had a direct influence on
first-order factors (physical, psychological, social and environment) has been reported to have a
better fit compared to other one-factor models (Masthoff, et al., 2005; Miller, et al., 2008;
Skevington, et al., 2004; Xia, et al., 2012; Yao, et al., 2002). The instrument also been shown to
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demonstrate reasonable known-groups validity and reliability in diverse disease population
(Jang, et al., 2004; Jaracz, et al., 2006; Kim, et al., 2013; Skevington, et al., 2004; Xia, et al.,
2012; Yao, et al., 2002).
Although WHOQOL-BREF instrument has been previously used to assess QOL among
adults with autism (Jennes-Coussens, Magill-Evans, & Koning, 2006; Kamio, Inada, & Koyama,
2013; Kamp-Becker, Schroder, Remschmidt, & Bachmann, 2010), its psychometric properties
for independent use in this population is not yet tested. An instrument like WHOQOL-BREF
that has been developed for a general population may not hold its psychometric profile in a
disease population. Therefore, it is often suggested to test the validity, reliability, and
responsiveness of generic or disease-specific instruments in the same (Patrick & Deyo, 1989) as
well as different populations. The purpose of this study was to assess the construct validity
(factorial validity, convergent validity, discriminant validity and known-groups validity),
reliability (internal consistency) and floor and ceiling effect of WHOQOL-BREF instrument
among adults with autism spectrum disorders.
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METHODS
Study sample and procedure
A cross-sectional study using an Internet-based survey of adults with autism enrolled at
Interactive Autism Network (IAN) was performed using Qualtrics survey software program.
IAN, operated by Kennedy Krieger Institute, is the largest online research-based registry of
adults and children with autism and their caregivers in the US. The cover letter explaining the
purpose of the study, eligibility criteria, contact information and study link was emailed to the
participants. The respondents eligible for the study were required to be at least 18 years of age.
In addition, it was required that they could respond to the question with little or no proxy help.
Study approval was obtained from the University of Mississippi Institutional Review Board (UM
IRB) under exempt status.
This study is part of a bigger research study among adults with autism; however, only
information applicable to this study has been reported in this chapter. The survey included two
sections. Section I included four measures: WHOQOL-BREF, Brief Coping Orientation to
Problem Experiences (Brief-COPE; coping instrument), Interpersonal Support Evaluation List12 (ISEL-12; social support instrument), Waisman Activities of Daily Living Scale (functional
independence instrument) and Autism-Quotient 10 (AQ-10; autism severity instrument). Section
II will include sociodemographic questions. The survey was open for a period of month between
August 29, 2013 and September 19, 2013. Survey respondents were assured confidentiality of
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responses and data anonymity. A $5 incentive (Amazon gift-card) for participation was provided
to the study participants.
Measures
Quality of life
WHOQOL-BREF contains 26-items, including one item on overall QOL and one item on
general health (Skevington, et al., 2004). The remaining 24-items are measured on a five-point
scale classified into four domains: physical health (seven items), psychological health (six
items), social relationships (three items) and environment (eight items). There are three reversed
coded items in the questionnaire. The raw scores for each domain were calculated by adding the
scores of the item in each domain. The raw scores were further transformed to 0-100 by using an
algorithm provided by the WHOQOL-BREF group (World Health Organization, 1996). Lower
score indicate poor QOL.
Autism severity
AQ-10 is a self-reported shorter version of the 50-item parent version AQ (Allison, Auyeung, &
Baron-Cohen, 2012). The 10-item AQ is measured on a four-point Likert scale (strongly agree,
slightly agree, slightly disagree, strongly disagree). The instrument captures severity in five
domains including social interaction, communication, attention to detail, attention switching and
imagination. A total score is assessed by summing score on all the items, with higher score
indicating greater severity of autistic behavior. Based on a cut-off value of six, individuals can
be classified into low and high severity (Allison, et al., 2012).
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Analysis
Items distribution and quality
Descriptive statistics including mean, standard deviation (SD), median, and missing data (%)
were reported. Kurtosis and skew coefficients were calculated to check for normality. The
absolute value greater than 1.0 indicates problems with the distribution.
Construct validity
Correlation analyses
WHOQOL-BREF domain to domain correlation was performed using Pearson correlation
coefficient. Correlation between WHOQOL-BREF items with the domains as well overall QOL
and general health item was also reported using Pearson correlation coefficient. In order to
establish validity of WHOQOL-BREF instrument, the association of each domain with respect to
general health and overall QOL was assessed using linear regression.
Convergent and discriminant analyses
Convergent and discriminant validity of WHOQOL-BREF was determined by testing several
relationships using corrected item-total correlation and item-to-other scale correlation. For
convergent validity, the expected items in the same domain should correlate strongly with each
other compared to the items from other domains. For discriminant validity, the items from
different domains should have a low or no correlation with each other. Convergent and
discriminant validity was demonstrated by examining corrected item-total correlation between
individual items in a domain with total score of the remaining items in the same or other
domains. The corrected-item total correlation should be higher for similar domains compared to
corresponding domains (at least ≥0.40) to demonstrate convergent validity. For discriminant
validity, the corrected item-to-other scale correlation should be lower for unrelated domains.
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Confirmatory factor analysis
Hypothetical structure of the WHOQOL-BREF instrument was validated using confirmatory
factor analysis (CFA). The assumptions of multivariate normality and linearity were evaluated
by checking significance in skew and kurtosis index (Harrington, 2008; Kline, 2010). The
model’s fit was determined using different fit indices (Harrington, 2008; Kline, 2010; Schreiber,
Nora, Stage, Barlow, & King, 2006). Most common fit indices are Normed Fit Index (NFI),
Non-Normed Fit Index (NNFI, also known as TLI), Incremental Fit Index (IFI), Comparative Fit
Index (CFI), root mean square error of approximation (RMSEA) and root mean square residual
(SRMR). The criteria suggested for good fit of the model are NFI>.90, TLI>.95, IFI>.90,
CFI>.95, RMSEA<.06 and SRMR<.08. Similar to the studies in the past, the most commonly
tested CFA models were compared in this study: one factor model and second-order model
(Masthoff, et al., 2005; Miller, et al., 2008; Skevington, et al., 2004; Xia, et al., 2012; Yao, et al.,
2002). For one-factor model, all the items are said to have a direct effect on QOL. For the
second model (Figure 2.1), the second-order factor (QOL) is said to have a direct effect on each
first-order factor (physical, psychological, social relationship and environment). In order to
determine which model fits the data best, akaike information criteria (AIC; smaller is better) fit
indices were calculated for nested models (Kline, 2010). CFA was conducted using IBM SPSS
AMOS 22.0 (IBM Corporation, Armonk, NY, US) statistical software.
Known-groups validity
The most important factor to consider when validating a QOL questionnaire is whether it can
discriminate between different levels of disease severity. A cut-off of six was used to
differentiate between high and low levels of severity groups (Allison, et al., 2012). Independent
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sample t-test was conducted to test whether the WHOQOL-BREF instrument can discriminate
between different levels of autism severity.
Reliability
The internal reliability of WHOQOL-BREF was assessed by means of Cronbach’s coefficient
alpha. Internal consistency reliability ≥0.70 is considered adequate, with values

0.80

considered preferable (Gliem & Gliem, 2003; Nunnally & Bernstein, 1994).
Floor and ceiling effect
The floor effect was determined by calculating the percentage of respondents selecting the
lowest possible score on a five-point scale of each item. The ceiling effect is determined by
calculating the percentage of people choosing the highest possible score on a five-point scale of
an item. The following criteria for floor and ceiling effects were used: no floor or ceiling effect
(excellent); floor or ceiling effect ≤20% (adequate) and floor or ceiling effect ≥20% (poor)
(McHorney & Tarlov, 1995).
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RESULTS
Socio-demographic characteristics
The final study sample consisted of 265 adults with autism (Table 2.1). Majority of the study
participants were male (56%), white (83%), and had a mean age of 33.1 (±13.76) years. Around
63% had a diagnosis of Aspergers syndrome followed by classic autism (~22%) and PDD-NOS
(~13%). Participants also reported having other mental (48.1%) and physical illnesses (~41%)
besides being diagnosed with autism.

Table 2.1: Study sample characteristics (N=265)
Characteristic
N (%)
Age (in years), Mean (SD)
33.08 (±13.76)
Male, N (%)
147 (55.7)
White, N (%)
218 (82.6)
Insurance status, N (%)
Public
112 (42.4)
Private including HMO
120 (45.5)
No insurance
30 (11.4)
Residential Status, N (%)
Living independently
77 (29.2)
Living with a partner
55 (20.8)
Living with family
120 (45.5)
Living in a supported home (group home)
10 (3.8)
Primary diagnosis, N (%)
Classic autism/autistic disorder
59 (22.3)
Asperger’s syndrome
166 (62.9)
PDD-NOS
35 (13.3)
Occupation
Employed/Self-employed full-time
62 (23.5)
Employed part-time
39 (14.8)
Student
54 (20.5)
Seeking work
39 (14.8)
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Other
70 (26.5)
Other physical illness (yes), N (%)
108 (40.9)
Other mental illness (yes), N (%)
127 (48.1)
PDD-NOS, Pervasive Developmental Disorder, Not Otherwise
Specified

Items distribution and quality
The mean score, kurtosis and skewness coefficients and missing data on the WHOQOL-BREF
items were assessed (Table 2.2). Mean scores of all 26 items of WHOQOL-BREF ranged from
2.70 (±1.23; item 21) to 3.82 (±1.01; item 15) on a 5-point response scale. The mean score and
the SD of the individual domains were 58.90 (±18.26) for physical health, 54.59 (±16.98) for
psychological health, 48.26 (±23.29) for social relationships and 58.12 (±17.96) for environment
domain. Majority of the WHOQOL-BREF items have kurtosis and skewness coefficient within
the acceptable range of -1.00 to 1.00. Three items were slightly outside the range for kurtosis
coefficient but still less than 1.11. Based on the ranges, the data appeared to be normally
distributed. Total missing data was around 3.7% (total items) with 0.0%-0.7% missing data on
individual items. No items were deleted because we had minimal missing data (<20%) (World
Health Organization, 1996). Mean-substitution was used to replace item scores where there was
only one item missing within a domain. Only one respondent had more than 2 items missing for
the same domain (environment). For that respondent, the domain score was not calculated.
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Table 2.2: Summary statistic of the WHOQOL-BREF instrument
Items*
Mean (SD) Median Missing Skewness Kurtosis Floor (%) Ceiling (%)
Overall QOL (item 1)
3.63 (0.89)
4
-0.395
-0.389
0.4
14.0
0.00%
General health (item 2)
3.18 (1.04)
3
-0.095
-0.941
3.4
8.3
0.00%
Pain (item 3)
3.71 (1.10)
4
-0.448
-0.743
29.2
2.3
0.00%
Medication (item 4)
3.49 (1.16)
4
-0.359
-0.773
22.3
5.3
0.00%
Positive feeling (item 5)
3.40 (0.93)
3
-0.18
-0.339
1.9
10.6
0.00%
Spirituality (item 6)
3.21 (1.01)
3
-0.278
-0.441
5.3
8.0
0.38%
Think (item 7)
3.16 (0.95)
3
-0.062
-0.402
3.4
7.2
0.38%
Safety (item 8)
3.53 (0.93)
4
-0.563
0.002
2.3
11.4
0.38%
Environment (item 9)
3.55 (0.93)
4
-0.424
0.002
2.3
13.6
0.38%
Energy (item 10)
3.10 (0.95)
3
-0.205
-0.35
4.9
4.9
0.00%
Body (item 11)
3.08 (1.04)
3
-0.283
-0.651
7.6
5.3
0.00%
Finance (item 12)
2.72 (1.20)
3
0.12
-0.944
19.3
6.8
0.38%
Information (item 13)
3.45 (0.98)
4
-0.426
-0.284
3.0
12.1
0.00%
Leisure (item 14)
3.25 (1.12)
3
-0.11
-0.83
5.3
14.4
0.38%
Mobility (item 15)
3.82 (1.01)
4
-0.54
-0.473
1.1
29.2
0.00%
Sleep (item 16)
3.00 (1.19)
3
-0.178
-1.114
12.1
7.2
0.00%
Activities (item 17)
3.31 (1.05)
3
-0.337
-0.628
4.5
10.2
0.00%
Work (item 18)
3.09 (1.27)
3
-0.071
-1.118
12.1
15.5
0.00%
Esteem (item 19)
3.35 (1.10)
3
-0.255
-0.763
4.5
14.8
0.38%
Relationship (item 20)
2.99 (1.15)
3
-0.18
-0.971
11.7
6.8
0.00%
Sex (item 21)
2.70 (1.23)
3
0.102
-0.877
23.1
8.3
0.75%
Support (item 22)
3.10 (1.10)
3
-0.203
-0.619
9.1
9.1
0.00%
Home (item 23)
3.29 (1.21)
3
-0.182
-1.076
6.4
18.2
0.38%
Services (item 24)
3.29 (1.15)
3
-0.26
-0.897
6.1
14
0.00%
Transportation (item 25)
3.53 (1.16)
4
-0.597
-0.391
7.2
20.8
0.00%
Negative feeling (item 26) 2.92 (1.00)
3
-0.198
-0.628
3.0
9.1
0.00%
SD, Standard deviation; WHOQOL, World Health Organization Quality of Life
* Items are measured on 5-point response scale

Construct validity
Correlation analyses
Domain to domain correlations
Pearson Correlations between WHOQOL-BREF domains ranged from 0.332 between social
relationship and physical health to 0.662 between physical health and environment (Table 2.3).

Table 2.3: Inter-correlation of the WHOQOL-BREF domains
Physical
Psychological
Social
Environment
Health
Health
Relationships
Psychological
.594**
Health
Social
.332**
.550**
Relationships
Environment
.622**
.615**
.441**
WHOQOL, World Health Organization Quality of Life
**correlation significant at p<0.001 level

Item to domain correlations
The strength of association between corresponding domains, general health item and overall
QOL items with individual items were assessed using Pearson correlation (Table 2.4).
Correlation coefficients ranged from r=0.168 to r=0.761 for physical domain, r=0.242 to
r=0.724 for psychological domain, r=0.122 to r=0.835 for social relationships domain, r=0.218
to r=0.739 for environment domain, r=0.244 to r=0.510 for overall QOL item and r=0.176 to
r=0.475 for general health item. None of the items had a stronger correlation with other
corresponding domains compared to its original domain.
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Table 2.4: Item-to-domain inter-correlations of the WHOQOL-BREF
Overall QOL General health Physical Psychological
Social
Environment
(item 1)
(item 2)
health
health
Relationships
Pain (item 3)
0.340**
0.475**
0.659**
0.242**
0.122*
0.341**
Medication (item 4)
0.298**
0.464**
0.642**
0.247**
0.146*
0.267**
Positive feeling (item 5)
0.421**
0.284**
0.383**
0.709**
0.369**
0.387**
Spirituality (item 6)
0.430**
0.312**
0.383**
0.724**
0.361**
0.445**
Think (item 7)
0.264**
0.271**
0.360**
0.611**
0.286**
0.356**
Safety (item 8)
0.419**
0.252**
0.400**
0.384**
0.162**
0.649**
Environment (item 9)
0.383**
0.396**
0.505**
0.463**
0.281**
0.597**
Energy (item 10)
0.370**
0.460**
0.689**
0.508**
0.281**
0.432**
Body (item 11)
0.304**
0.386**
0.422**
0.634**
0.420**
0.424**
Finance (item 12)
0.402**
0.257**
0.348**
0.419**
0.359**
0.625**
Information (item 13)
0.457**
0.336**
0.464**
0.466**
0.367**
0.730**
Leisure (item 14)
0.387**
0.288**
0.388**
0.386**
0.325**
0.659**
Mobility (item 15)
0.360**
0.345**
0.584**
0.274**
0.191**
0.459**
Sleep (item 16)
0.299**
0.367**
0.600**
0.415**
0.232**
0.397**
Activities (item 17)
0.510**
0.420**
0.761**
0.561**
0.307**
0.573**
Work (item 18)
0.345**
0.438**
0.699**
0.506**
0.267**
0.435**
Esteem (item 19)
0.376**
0.373**
0.462**
0.690**
0.350**
0.435**
Relationship (item 20)
0.398**
0.310**
0.306**
0.507**
0.835**
0.408**
Sex (item 21)
0.244**
0.176**
0.168**
0.351**
0.812**
0.218**
Support (item 22)
0.428**
0.254**
0.336**
0.474**
0.759**
0.449**
Home (item 23)
0.404**
0.250**
0.422**
0.388**
0.309**
0.676**
Services (item 24)
0.458**
0.313**
0.456**
0.414**
0.267**
0.739**
Transportation (item 25)
0.327**
0.227**
0.345**
0.359**
0.251**
0.627**
Negative feeling (item 26)
0.401**
0.341**
0.391**
0.693**
0.444**
0.444**
WHOQOL, World Health Organization Quality of Life
**correlation significant at p<0.01 level; *correlation significant at p<0.05 level

Convergent and discriminant validity
Corrected item-total correlation and item-to-other scale correlation was calculated in order to
demonstrate convergent and discriminant validity of WHOQOL-BREF instrument (Table 2.5).
Corrected item-total correlation ranged from 0.420 to 0.652 for physical health, 0.431 to 0.562
for physiological health, 0.489 to 0.608 for social relationships and 0.471 to 0.633 for
environment domain. The correlation of the items with their own domain was found to be at
least 0.40 suggesting acceptable convergent validity. For majority of items, item-to-other scale
correlation (discriminant validity) was found to be lower than 0.40. Item-to-other scale
correlation for physical health ranged from 0.362 to 0.459 with physiological health, 0.169 to
0.38 with social relationships and 0.341 to 0.505 with environment domain, respectively. For
other domains, in general, the item-to-other scale coefficient ranged from 0.245 (item 3; physical
health) to 0.562 (item 17; physical health) for physiological health, 0.124 (item 3; physical
health) to 0.442 (item 26; physiological health) for social relationships and 0.218 (item 21; social
relationships) to 0.573 (item 17; physical health) for environment domain supporting
discriminant validity for the instrument.
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Table 2.5: Convergent and discriminant validity for WHOQOL-BREF items
Physical Psychological
Social
Environment
Health
Health
Relationships
Physical health
Pain (item 3)
0.245
0.124
0.341
0.510
Medication (item 4)
0.250
0.147
0.267
0.478
Energy (item 10)
0.509
0.282
0.432
0.572
Mobility (item 15)
0.274
0.191
0.459*
0.430
Sleep (item 16)
0.416
0.233
0.397
0.420
Activities (item 17)
0.562
0.307
0.573
0.652
Work (item 18)
0.507
0.268
0.435
0.533
Psychological health
Positive feeling (item 5)
0.388
0.369
0.387
0.563
Spirituality (item 6)
0.386
0.362
0.445
0.569
Esteem (item 19)
0.459
0.350
0.435
0.499
Think (item 7)
0.362
0.287
0.356
0.431
Body (item 11)
0.424
0.421
0.424
0.441
Negative feeling (item 26)
0.385
0.442
0.444
0.522
Social relationships
Relationship (item 20)
0.305
0.507
0.408
0.608
Sex (item 21)
0.169
0.351
0.218
0.538
Support (item 22)
0.338
0.475
0.449
0.489
Environment
Safety (item 8)
0.400
0.384
0.162
0.540
Environment (item 9)
0.505*
0.463
0.281
0.478
Finance (item 12)
0.348
0.420
0.359
0.471
Information (item 13)
0.465
0.467
0.368
0.633
Leisure (item 14)
0.390
0.387
0.326
0.526
Home (item 23)
0.423
0.389
0.309
0.534
Services (item 24)
0.457
0.415
0.267
0.624
Transportation (item 25)
0.341
0.357
0.250
0.480
WHOQOL, World Health Organization Quality of Life
Values are based on corrected total-item correlation
Bold font highlights the corrected total-item correlation with its own domain.
*Italics font suggests the highest corrected total-item correlation with other domain
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Association of domains with general facet items
In order to establish construct validity of WHOQOL-BREF instrument, the association of each
domain with respect to overall QOL and general health was also assessed (Table 2.6). The
overall QOL was strongly associated with environment and psychological domains whereas
general health was strongly associated with physical health domain. The contribution of domain
score on overall QOL and general health was also studied using multiple regression. For overall
QOL item, physical, social relationships and environment domains had significantly positive
contribution after controlling for other variables (p<0.01). Roughly 44% (adjusted r2) of
variance on overall QOL was explained by the underlying domains. Physical health (β=0.031;
p<0.001) and psychological health (β=0.009; p=0.035) have significantly predictive effect on
general health item after controlling for other variables. The variance explained by all the
domains on the general health was around 42% (adjusted r2).

Table 2.6: Regression analysis and correlation of WHOQOL-BREF domains with general facet
items
Adjusted
Physical Psychological
Social
Environment
R2
Health
Health
Relationships
Overall
0.540**
0.439**
0.609**
Correlation 0.536**
0.44
QOL
0.010**
0.007
0.006**
0.014**
Β
General
0.486**
0.304**
0.432**
Correlation 0.638**
0.42
Health
0.031**
0.009*
0.002
-0.001
Β
WHOQOL, World Health Organization Quality of Life
**p<0.05
β values are based on linear regression
Confirmatory factor analysis
Tables 2.7 and 2.8 summarize the results from CFA analysis for the two models tested.
Comparison was made between one-factor model and a four-factor hierarchical model. A poor
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fit was observed for the one-factor model (Chi-square[df] =766.37[252], p<0.05; GFI=0.792;
AGFI=0.752, CFI=0.752 and RMSEA=0.08 [0.081-0.095]). The second-factor model fit was
found to be comparatively good: Chi-square(df) =575.35 (248), p<0.05; GFI=0.847;
AGFI=0.841, CFI=0.842 and RMSEA=0.071 (0.063-0.078). Based on the modification indices,
six pairs of items were correlated in the second factor model. The model fit improved
substantially when error terms for items 3 and 4, items 5 and 6, items 9 and 10, items 18 and 19,
items 9 and 23 and items 15 and 25 were covaried. The model fit of the of the final model
improved significantly: Chi-square(df) =428.00 (242), p<0.05; GFI=0.885; AGFI=0.858,
CFI=0.885 and RMSEA=0.054 (0.046-0.062). The final model is depicted in Figure 2.1. The
revised hierarchical second-order model was more parsimonious and represented a significantly
better fit compared to hierarchical second-order factor and first-order factor model (χ2 difference
=191.02, df=4; p<0.001). In the final modified model, factor loadings of all the items on their
corresponding domains as well first-order factor loadings on QOL (second-order factor) were
found significant (p<0.001; Table 2.8).

Table 2.7: Goodness to fit for confirmatory factor analysis analyses for WHOQOL-BREF
instrument
First-order model
Four second-order hierarchical model
Chi-square (DF)
766.37 (252)***
428.002 (242)***
CFI (>0.90)
0.752
0.91
GFI (>0.90)
0.792
0.885
AGFI (>0.80)
0.752
0.858
RMSEA (0.06-1)
0.08 (0.081-0.095)
0.054 (0.046-0.062)
AIC (smaller is better)
862.366
544.002
WHOQOL, World Health Organization Quality of Life
***p<0.001
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Table 2.8: Unstandardized estimation of four second-order hierarchical model
First-order factor loading
Second-order factor loading
2
Estimation (SE)
R
Estimation (SE)
R2
1.000
0.702
Physical health
Pain (item 3)
0.586 (0.090)
0.206
Medication (item 4)
0.565 (0.094)
0.172
Energy (item 10)
0.693 (0.078)
0.402
Mobility (item 15)
0.565 (0.082)
0.229
Sleep (item 16)
0.745 (0.098)
0.287
Activities (item 17)
0.973 (0.092)
0.631
Work (item 18)
1.000
0.45
0.851 (0.111)
0.942
Psychological health
Positive feeling (item 5)
0.841 (0.110)
0.326
Spirituality (item 6)
0.947 (0.121)
0.347
Esteem (item 19)
0.745 (0.110)
0.371
Think (item 7)
0.958 (0.123)
0.242
Body (item 11)
1.071 (0.132)
0.336
Negative feeling (item 26)
1.000
0.393
0.707 (0.107)
0.488
Social relationships
Relationship (item 20)
1.240 (0.141)
0.605
Sex (item 21)
1.045 (0.133)
0.378
Support (item 22)
1.000
0.434
0.717 (0.108
0.724
Environment
Safety (item 8)
0.896 (0.128)
0.34
Environment (item 9)
0.816 (0.124)
0.281
Finance (item 12)
1.103 (0.163)
0.308
Information (item 13)
1.162 (0.148)
0.509
Leisure (item 14)
1.135 (0.158)
0.374
Home (item 23)
1.145 (0.167)
0.324
Services (item 24)
1.306 (0.170)
0.471
Transportation (item 25)
1.000
0.276
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Figure 2.1: Confirmatory factor analysis on the second-order factor
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Known-groups validity
The ability of the WHOQOL-BREF instrument to discriminate between low and high severity
groups was tested using the independent sample t-test (Table 2.9). The mean scores were
significantly higher for group 1 (low severity) compared to group 2 (high severity) for physical
health (61.2±18.1 vs. 56.8±18.0; p=0.03) and physiological (58.3±15.8 vs. 51.6±17.5; p=0.002)
health domains. There was no significant difference in social relationships and environment
domains scores between low and high autism severity groups (p>0.05).

Table 2.9: Known-groups validity for the WHOQOL-BREF domains
Autism Severity
Domains
Low severity (N=116)
High severity (N=143)
61.70 (18.07)
56.77 (18.03)
Physical health
58.26 (15.80)
51.60 (17.45)
Psychological health
50.00 (22.74)
46.97 (23.83)
Social Relationships
60.16 (16.53)
56.75 (19.15)
Environment
WHOQOL, World Health Organization Quality of Life
Values are presented as mean (standard deviation )
P values are based on independent t-test

p value
0.030
0.002
0.300
0.132

Internal consistency
The overall Cronbach’s alpha was found to be 0.914 for 26 items (Table 2.10). Cronbach’s
alpha for individual domains were 0.784 for physical health (7 items), 0.761 for psychological
health (6 items), 0.722 for social relationships (3 items) and 0.815 for environment (8 items),
respectively. The corrected-item correlation was also found to be within the range (0.4300.651), suggesting that the items have good correlation with the other items in the same domain.
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Table 2.10: Reliability for the WHOQOL-BREF domains
Mean (SD) Cronbach's Alpha No. of items
58.90 (18.26)
0.784
7
Physical health
0.761
6
Psychological health 54.59 (16.98)
0.722
3
Social relationships 48.26 (23.29)
58.12 (17.96)
0.815
8
Environment
0.914
26
Overall
WHOQOL, World Health Organization Quality of Life

Floor and ceiling effect
Table 2.2 displays the results for floor and ceiling effects. The floor and ceiling effects were
non-existent with the exception of three items which displayed floor effects (items 3, 4 and 21)
and two items which displayed ceiling effects (items 15 and 25).

40

DISCUSSION
Though a few studies have used the WHOQOL BREF to assess QOL among adults with autism,
the psychometric properties of this instrument in this population remains unknown. To the best
of our knowledge, this is the first study to assess psychometric properties of WHOQOL-BREF
instrument among adults with autism. Study results depicted acceptable construct validity and
know-group validity of WHOQOL-BREF instrument in this population. The reliability of the
instrument was also found to be reasonable. Floor and ceiling effects were limited.
Domain structure and distribution of WHOQOL-BREF scores
Majority of participants reported good overall QOL and were on average satisfied with their
health. With respect to individual domain scores, the mean score for physical health was 58.90
(±18.26), psychological health was 54.59 (±16.98), social relationships was 48.26 (±23.29) and
environment was 58.12 (±17.96). The participants reported more than average scores for vast
majority of items as well as all domains. This suggests that overall, adults with autism valued
their QOL in a positive direction. The mean score for item 12, which is regarding having enough
money to meet their needs, was 2.72. This is understandable because individuals with autism
struggle to be independent and do not have a suitable source of employment (Hendricks, 2010; J.
Taylor & Seltzer, 2011). In our study, only ~38% of the respondents were employed fulltime/part-time. Two items from social relationships domain also had mean below average. The
participants were not that satisfied with their personal relationships (item 20; mean=2.99) and
they were not satisfied with their sex life (item 21; mean=2.70). This is also not alarming as
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autistic individuals struggle with their social skills and personal relationships (Orsmond, Krauss,
& Seltzer, 2004). Not surprisingly, for item 26 (mean=2.92) belonging to the psychological
domain, participants reported that they “seldom” to “most often” had negative feelings such as
blue mood, despair, anxiety and depression. Multiple studies have shown depression and anxiety
as common psychiatric comorbidities among adults with autism (Gillott & Standen, 2007; Joshi
et al., 2013). Missing data for WHOQOL-BREF in this study was minimal in this study,
suggesting ease of understanding of the instrument among adults with autism.
Construct validity
As depicted in other studies, we also found significant correlation between the four domains
(physical, psychological, social and environment) in this study (Hanestad, et al., 2004;
Skevington, et al., 2004; Yao, et al., 2002). The highest correlation was found between
environment and physical domains. We also found significant correlation between four domains
with overall QOL and general health items supporting construct validity. This suggests that all
the domains positively contributed towards general health and overall QOL among adults with
autism. Physical health was the best predictor of general health, followed by psychological
heath. Environment, physical, and social health had significant positive influence on overall
QOL. The percentage of variance explained by all four WHOQOL-BREF domains was 44% for
overall QOL and 42% for general health.
We found good support for convergent and discriminant validity of WHOQOL-BREF in
our study. Based on the corrected item-total correlation and item-to-other scale correlation
values, we found higher correlation between items and their theoretically related domains and
lower correlation with other theoretically un-related domains in this study for vast majority of
items. Two items did have higher correlation with other domains. Item 15 related to mobility
42

(“how well are you able to get around?” which is part of physical domain) had a higher
correlation with environment domain. This may reflect an overlap in the underlying content of
these two items. Nevertheless, both items still had more than acceptable correlation coefficient
(r>0.04) with their own domains. Therefore, our data provides support for convergent and
discriminant validity among adults with autism.
Factorial validity of WHOQOL-BREF instrument was tested by comparing one-factor
model and four-factor hierarchical model. Studies in the past have conceptualized WHOQOLBREF as a second-order model where the second-order QOL (a latent variable) had direct effects
on first-order factors (measured variables) such as physical health, psychological health, social
relationships and environment domains (Masthoff, et al., 2005; Miller, et al., 2008; Skevington,
et al., 2004; Xia, et al., 2012; Yao, et al., 2002). We found similar results where second-order
model was found to have a better fit for adults with autism. Minor modifications driven by data
were made where error covariance were added between a few items to improve the model fit
based on modification indices. For example, error covariance between items 3 (physical pain
prevents daily activities) and 4 (need treatment to enjoy daily life) was correlated. It is likely
that people experiencing physical pain and discomfort which is preventing them from doing
routine activities will seek some kind of treatment to enjoy their everyday life. Similar to the
findings in the general population, final four-factor model (with error covariance) of WHOQOLBREF instrument was supported in the population of adults with autism. This further proves the
generic use of this instrument and acceptable factorial validity among adults with autism.
Known-groups validity
The result of this study does not demonstrate full support for known-groups validity of
WHOQOL-BREF instrument for adults with autisms. Significant differences between high and
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low autism severity groups for physical and psychological health domains were observed;
however, no significant difference for scores on social relationships and environment domains
were found. While considering only the mean scores for social relationships and environment
domains, expected direction was found where the domain scores were higher for low severity
group with respect to high severity group. A few studies in the past comparing healthy and
unhealthy groups have found weaker (Skevington, et al., 2004) or no discriminative power for
environmental domain (Jang, et al., 2004; Jaracz, et al., 2006; Xia, et al., 2012; Yao, et al., 2002).
The situational nature of environment domain, and its general lack of relation with an
individual’s health may explain the lack of emergence of known-groups validity for this domain
of WHOQOL-BREF (Xia, et al., 2012). No statistical difference between low and high severity
groups for social relationship domain was observed. Researchers who are planning to use the
WHOQOL-BREF instrument in this population may consider the inclusion of additional items
specific to adults with autism to increase the discriminating ability of social relationships
domain.
Internal consistency
Internal consistency was measured using Cronbach’s alpha in this study. We found excellent
support for the reliability in this study with alpha coefficient of 0.91 for all items, and
Cronbach’s alpha above 0.70 across all domains. Unlike other studies (Hanestad, et al., 2004;
Jaracz, et al., 2006; Masthoff, et al., 2005; Nedjat, et al., 2008; Skevington, et al., 2004; W. J.
Taylor, et al., 2004; Trompenaars, et al., 2005; Yao, et al., 2002), we also found acceptable
internal consistency support for social relationships domain (α=0.72) among adults with autism
in the US.
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Floor and ceiling effect
Floor and ceiling effects for WHOQOL-BREF were not observed in this population with the
exception of three items displaying floor effect and two items displaying ceiling effect. The
highest floor effect is depicted by item 3 (pain; 29.3%) and the highest ceiling effect by item 15
(mobility; 29.3%). Overall, the items were not skewed, indicating their acceptability for future
use in this population.
Study limitations
A few limitations should be considered while interpreting the results of this study. Our sample
included adults with autism who answered the questionnaire with little or no help from their
caregivers. This may have resulted in higher representation of adults with Asperger’s syndrome
or high functioning autism. Further, only those adults who were members of the IAN were
invited for participation. Therefore, the results of this study cannot be generalized to all adults
with autism in the US. Considering the cross-sectional research design of this study, concurrent
validity, predictive validity and test-retest reliability of the WHOQOL BREF were not
determined. Future studies could use a longitudinal design to merit these properties.
Conclusion
Our result demonstrates a clear support for the psychometric properties of generic WHOQOLBREF instrument in terms of its construct validity, reliability and floor and ceiling effects.
Partial support for known-groups validity of the WHOQOL BREF was found among adults with
autism. Study results indicate that the WHOQOL BREF is a suitable instrument for the
assessment of QOL among adults with autism. Until autism specific QOL instruments are
developed, researchers and providers could use this instrument for QOL outcome assessment in
this growing population.
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CHAPTER 3
QUALITY OF LIFE AMONG ADULTS WITH AUTISM SPECTRUM DISORDERS
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INTRODUCTION
Autism spectrum disorders are neurodevelopmental diseases interfering with brain activity
leading to limited social communication and repetitive and restrictive behavior. One in 68
children have autism in the United States (US) (MMWR, 2014). Though estimates of autism
prevalence among adults in the US are lacking, in a study conducted in the United Kingdom
(UK), the prevalence of autism among adults was reported to be ~1% (Brugha et al., 2011).
Autism is more prevalent among males compared to females (MMWR, 2014).
Assessing patients’ quality of life (QOL) is gaining more recognition and is considered to
be a clinically meaningful outcome for providers and researchers across several disease
conditions including autism. With increase in life expectancy, researchers and clinicians are
focusing on nonclinical factors such as QOL along with clinical factors to improve health and
wellbeing of an individual. QOL is a multidimensional construct, which includes the physical,
psychological, social, and environmental health of an individual. It assesses an individual’s
perception of their position in life, and the role of health and non-health-related factors in
influencing those perceptions (WHOQOL, 1997). A few studies have found adults with autism
to have poor physical and psychological health as compared to healthy peers or those with other
disorders (Billstedt, Gillberg, & Gillberg, 2011; Eaves & Ho, 2008; Jennes-Coussens, MagillEvans, & Koning, 2006; Kamio, Inada, & Koyama, 2013; Kamp-Becker, Schroder, Remschmidt,
& Bachmann, 2010; Khanna, Jariwala-Parikh, West-Strum, & Mahabaleshwarkar, 2014). For
example, Kamp-Becker et al. (2010) found lower QOL among adults with autism as compared to
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adults with diabetes; however, the authors did report these adults to have better QOL as
compared to adults with schizophrenia. In the only such study conducted among adults with
autism in the US, Khanna et al. (2014) found lower physical and mental health-related quality of
life (HRQOL) among adults with autism than the general population. The study found social
support and coping to have a direct influence on HRQOL. It should be noted that Khanna et al.
(2014) studied HRQOL and not QOL, which is a more broader construct. To date, no study has
assessed QOL among adults with autism in the US.
Using a theoretical framework can enable one to better understand QOL and its
underlying predictors. Wilson and Cleary’s (1995) QOL model is the most commonly cited and
extensively used conceptual model for QOL. The model was developed with the intention of
integrating clinical variables with social science paradigm. There are five key dimensions of
health outcomes in this model which are linked by causal pathways (Ferrans, Zerwic, Wilbur, &
Larson, 2005; Wilson & Cleary, 1995): (1) biological and physiological factors, (2) symptom
status (“physical, emotional, and cognitive symptoms perceived by a patient”), (3) functional
status (“physical, psychological, social, and role function”), (4) general health perception
(“patient’s subjective rating of their health”), and (5) overall QOL (“how happy or satisfied
someone is with life as a whole”). In addition, individual and environmental factors are included
as mediating variables (see Figure 3.1). Wilson and Cleary’s QOL model has been widely
applied in its original or modified form in several different disease population, including HIV,
cancer, opioid-dependent patients, kidney transplant patients, solid organ transplant patients,
childhood cancer survivors and others (Devine et al., 2011; Ferrans, et al., 2005; Heslin et al.,
2011; Maurice-Stam, Oort, Last, & Grootenhuis, 2009; Nokes et al., 2011; Schulz et al., 2012;
Wettergren, Bjorkholm, Axdorph, & Langius-Eklof, 2004). For example, Maurice-Stam et al.
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(2005) utilized Wilson and Cleary’s QOL model along with Lazarus and Folkman’s model
(1984) as a guiding framework to propose a new model where background characteristics and
personal and psychosocial factors (such as course of life, coping, social support, family
functioning and communication about the disease) influence QOL among young adult survivors
of childhood cancer.
For the purpose of this study, Wilson and Cleary’s theoretical model was used as a
guiding framework to study QOL among adults with autism. The modified model excluded
biological and physiological variables from the original model because they are difficult to
measure using survey-based research. Consistent with the original Wilson and Cleary’s QOL
model, a direct and an indirect path between autism severity and QOL was included in the
modified model used in this study. As in the original model, a direct path between coping
(adaptive and maladaptive coping), functional independence, and social support and QOL was
included in the modified model used in this study (see Figure 3.1).
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Figure 3.1: Proposed study model based on modified Wilson and Cleary’s (1995) model
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The relationship between QOL and autism severity has not been clearly established in the
literature; however, a few studies have found autism severity to have an influence on outcomes
among adults with autism (Howlin, Goode, Hutton, & Rutter, 2004; Kamio, et al., 2013; Khanna,
et al., 2014). In lieu of past research in autism and previous studies of Wilson and Cleary’s
model, it was expected that autism severity would influence QOL among adults with the
disorder. This relationship was also considered to be mediated by coping, functional
independence, and social support. Coping is a process where individuals constantly make
cognitive and behavioral efforts to manage internal and external demands (Folkman, Lazarus,
Dunkel-Schetter, DeLongis, & Gruen, 1986). There are two types of coping mechanisms:
problem-focused coping and emotional-focused coping (Folkman, et al., 1986). Problemfocused coping is viewed as adaptive coping which focuses on a disease and changing the
situation to relieve the perceived problem. In contrast, emotional-focused (maladptive) coping,
also considered active or avoidant coping, diverts the attention from the disease and focuses on
changing the emotions and environment causing the stressful event (Abbott, Hart, Morton, Gee,
& Conway, 2008; Lazarus & Folkman, 1984). Though coping is not included in the original
Wilson and Cleary’s model, several studies across different diseases have found it to influence
QOL (Bucks et al., 2011; Burgess & Gutstein, 2007; Green, Pakenham, Headley, & Gardiner,
2002; Kaltsouda et al., 2011; Lua, Neni, & Samira, 2012; Maurice-Stam, et al., 2009; Ulvik,
Nygard, Hanestad, Wentzel-Larsen, & Wahl, 2008). When the situation seems manageable, it is
likely that an individual may adopt problem-focused coping strategies. However, when the
situation is not amenable, then it is likely that an individual will adopt emotional-focused coping
strategies (Tuncay, Musabak, Gok, & Kutlu, 2008). Adults with autism may face difficulty in
coping with the disorder, especially during their transition from childhood to adulthood, due to
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change in their daily life activities (McConachie, Hoole, & Le Couteur, 2011). Khanna et al.
(2014) found negative association between maladaptive coping and HRQOL among adults with
autism.
Functional independence is an important component that may influence QOL among
adults with autism. Compared to adults with Down syndrome, adults with autism have more
difficulties carrying out normal daily activities, have higher behavioral problems and receive
fewer services (Esbensen, Bishop, Seltzer, Greenberg, & Taylor, 2010). Functional
independence and its implications are more concerning once an individual with autism
transitions from childhood to adulthood.
Social support has been reported as a key predictor of QOL among adults with autism
(Burgess & Gutstein, 2007; Kamio, et al., 2013; Renty & Roeyers, 2006; Seltzer, Shattuck,
Abbeduto, & Greenberg, 2004). Social support received from family and friends can lead to
better outcomes among adults with autism (Seltzer, et al., 2004). Kamio et al. (2013) found a
significant relationship between mothers’ support and better QOL among adults with autism.
Burgress and Gutsein (2007) recommended including both subjective and objective measures of
social support as predictors of QOL among adults with autism. Subjective social support
indicates the presence of the social network, while objective social support indicates the actual
use of the available social network. Adults with autism require greater social support and
services, particularly during transition from childhood to adulthood (Hendricks & Wehman,
2009). Studies have reported no peer relationship among adults with autism irrespective of their
intellectual level (Howlin, et al., 2004; Orsmond, Krauss, & Seltzer, 2004). In this study, the
role of social support and its relationship with QOL among adults with autism will be examined.
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Several hypotheses will be tested in this study. First, it is hypothesized that greater
autism severity among adults with autism will be associated with lower QOL. Second, adults
with autism with better adaptive coping will have better QOL. Third, maladaptive coping will
have an adverse effect on QOL. Fourth, adults with autism who have lower functional
independence will experience lower QOL. Last, greater use of perceived social support among
adults with autism will result in a better QOL.
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RESEARCH DESIGN AND METHODS
Study design and sample
A cross-sectional, descriptive quantitative design was utilized in this study. An Internet-based
survey using Qualtrics survey software system (Qualtrics Inc., Provo, UT) was administered to
adults with autism enrolled with the Interactive Autism Network (IAN). IAN is the largest
national, Internet-based, voluntary research registry by Kennedy Krieger Institute and is
sponsored by Autism Speaks, the Simons Foundation, and the National Institute of Health (NIH)
(Hall, Huerta, McAuliffe, & Farber, 2012; IAN Website, 2014). The online IAN registry is
completely valid and participants are authenticated (Daniels et al., 2012). This makes an ideal
option for researchers to recruit patients at IAN. Study participants were eligible for this study if
they met the following criteria: 1) diagnosis of autism, Asperger syndrome or PDD-NOS from
healthcare professionals; 2) aged at least 18 years; and 3) can self-report the questionnaire with
little or no proxy help. The University of Mississippi’s Institutional Review Board (IRB)
approved (exempt status) this study.
Sample size and data collection
The relationship among variables listed in the theoretical model were studied using structural
equation modeling (SEM) (further detail on the technique is provided under the ‘Analysis’
section). Usually, a sample size of less than 100 is considered “small”, around 100-200 is
considered “medium” and greater than 200 cases is “acceptable” in SEM (Harrington, 2008;
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Kline, 2010). The general rule of thumb to calculate sample size where SEM is used is 10:1 (10
observations per indicator; Kline, 2010). There are 20 free parameters in this model to be
estimated (seven measurement error variances, 12 regression coefficients and one residual; see
Figure 3.2). Based on the recommendation of at least 10 cases per indicator, a minimum of at
least 200 participants were needed for this study.
An e-mail explaining the purpose of the study and a link to the online survey was
distributed to the eligible participants. The survey consisted of two parts. Part I included four
measures - WHOQOL-BREF, Brief Coping Orientation to Problem Experiences (Brief-COPE;
coping instrument), interpersonal support evaluation list-12 (ISEL-12; social support
instrument), Waisman Activities of Daily Living Scale (functional independence instrument) and
autism-quotient 10 (autism severity instrument). Part II included sociodemographic questions
about adults with autism. The survey was active for three weeks (August 29 – September 19,
2013). All data was collected anonymously, and response confidentiality was assured to
participants. Further, voluntary participation was emphasized. Responses were collected until
the desired sample size was achieved. As a token of appreciation, a $5 incentive was provided to
the participants who completed the survey.
Measures
QOL measure
A self-administered WHOQOL-BREF instrument, an abbreviated version of WHOQOL-100,
was used to assess QOL among adults with autism (Skevington, Lotfy, & O'Connell, 2004). The
instrument contains 26-items (one item on the 24 facets of QOL and two items measuring overall
QOL and general health facets) measured on a five-point Likert scale. The 24-facets can be
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further categorized into four domains: physical health (seven items), psychological health (six
items), social relationships (three items) and environment (eight items). The item scores for each
domain are transformed into a scale of 0-100 for easy comparison. Higher score indicates better
QOL on the corresponding domain.
Autism severity instrument
Autism Quotient-10 (AQ-10), a brief version of the 50-item AQ, was used to measure autism
severity among adults in this study (Allison, Auyeung, & Baron-Cohen, 2012). The scale
includes the domains of social interaction, communication, attention to detail, attention switching
and imagination. Responses were measured on a four-point Likert scale where 1= “strongly
agree”, 2= “slightly agree”, 3= “slightly disagree”, and 4= “strongly disagree”. A higher score
indicates more severity of autistic traits.
Coping instrument
Brief-COPE is a self-reported 28-item instrument to assess patients’ coping strategies in response
to a situation (Carver, 1997). Responses are rated on a four-point Likert scale (1=I haven‘t been
doing this at all to 4=I‘ve been doing this a lot). The psychometric properties of the Brief-COPE
have been thoroughly documented in literature (Carver, 1997). Brief-COPE has 14 subscales:
positive reframing, planning, humor, acceptance, religion, active coping, use of emotional
support, use of instrumental support, behavioral disengagement, self-distraction, venting, selfblame, denial, and substance use. The subscales are further categorized into two broad scales:
emotion-based (1-8) and problem-based coping (9-14). The wordings of the items were
modified for the present study in order to fit the study population. Reliability of Brief-COPE in
terms of internal consistency was acceptable (α =.50–.60; Carver, 1997).
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Functional independence instrument
Functional independence was assessed using the 17-item Waisman Activities of Daily Living
Scale (Maenner et al., 2013). The instrument is validated among adults with development
disorders including autism. It includes seventeen tasks such as making bed, household tasks,
errands, home repairs, laundry, bathing, grooming, dressing, toileting, simple food prep,
mixing/cooking, complete meals, set/clear tables, drink from the cup, eat from the plate, wash
dishes and banking finances. The items are rated based on the ability to perform tasks and
overall score is created by summing up the individual items. The task may be scored as
2=”independent or does on own”, 1=”does with help” or 0=”does not do at all” (total score range
0-34). Lower scores indicate higher dependence.
Social support instrument
Interpersonal Support Evaluation List (ISEL) is a 12-item global measure of perceived social
support. It has three domains: appraisal (availability of someone to interact with about
problems), tangible (instrumental support), and belonging (perceived availability of people with
whom one can do activities) (Cohen & Hoberman, 1983; Cohen, Mermelstein, Kamarck, &
Hoberman, 1985). It is measured on a four-point Likert scale ranging from Definitely True,
Probably True, Definitely False, or Probably False (range 12-48). The ISEL has acceptable
internal consistency (α=0.88-0.90) and good retest reliability for subscale ranges between 0.700.87 (Cohen, et al., 1985). Rogers et al., (2004) validated the ISEL scale among individuals with
mental illnesses. They found adequate psychometric properties (reliability and validity) of the
scale among individuals with mental illnesses. A higher score indicates greater extent of
perceived social support.
62

Sociodemographic characteristics
Age and age when diagnosed with autism (in years) were measured using an open-ended
question. Gender was categorized as males and females. Ethnicity was stratified in seven
categories: White, Black/African-American, Hispanic/Latino, American Indian/Alaskan Native,
Asian, Native Hawaiian/Pacific Islander and other. Insurance status was assessed as: public
insurance, private including HMO and no insurance. For residential status, four options (living
independently, living with a partner, living with family and living in a supported home) were
provided. Occupation was measured by asking if the adults were employed/self-employed fulltime, employed part-time, student, seeking work or other. Educational status was measured
using six categories: less than high school, high school graduate, some college, technical school,
college graduate and graduate school. Marital status was assessed if the adults had been never
married, not married/living with a partner, married, divorced/separated or widowed. Current
diagnosis included Asperger syndrome, classic autism, or PDD-NOS. Details on co-morbid
conditions, physical or mental disorders were also collected. Participants were asked if they
were (yes/no) taking prescription medications. The information on autism-related treatment
(yes/no) was also collected. Finally, respondents were asked if they required any assistance to
complete the questionnaire (Yes/No).
Analysis
Descriptive analyses were conducted for sociodemographic variables and other measures in the
study. Mean and standard deviations are reported for continuous items, and frequency and
proportions are reported for categorical items. Correlations between the study measures were
studied using Pearson’s correlation coefficient.
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As described earlier, SEM was used to study theoretical relationships. The assumptions
of multivariate normality and linearity were evaluated by checking significance in skew and
kurtosis index (Harrington, 2008; Kline, 2010). The absolute value of skew greater than 3.0 and
kurtosis index greater than 10.0 indicates problems with the distribution. Absolute value of
kurtosis index greater than 20.0 indicates serious problems with the underlying distribution of the
data. Maximum likelihood estimate requires large sample size and normally distributed indicator
variables. The model’s fit was determined using different fit indices such as Normed Fit Index
(NFI), Non-Normed Fit Index (NNFI, also known as TLI), Incremental Fit Index (IFI),
Comparative Fit Index (CFI), and root mean square error of approximation (RMSEA)
(Harrington, 2008; Kline, 2010; Schreiber, Nora, Stage, Barlow, & King, 2006). Following
criteria was used to assess the model’s fit: RMSEA < .06, TLI > .95, CFI > .95, root mean square
residual (SRMR) < .08. Akaike information criteria (AIC) goodness of fit indices was used for
nested models to assess the best fitting model (Kline, 2010). A smaller value of AIC indicates a
better fit. The relationship of QOL among autistic adults with other factors was studied using
SEM (model depicted in Figure 3.2). QOL was used as latent variable, while autism severity,
social support, emotional-focused coping, problem-focused coping, functional independence,
physical health, psychological health, social relationships and environment were considered as
measured variables. A significance level of p<0.05 was used for regression coefficients. SEM
analyses were conducted in SPSS AMOS version 22.0 (IBM Corporation, Armonk, NY, US).
Hierarchical linear regression was also used to predict factors affecting QOL among
adults with autism. The assumptions for linear regression were tested. Data was checked for
violation of linearity, homoscedasticity, independence and normality (Hair, Black, Babin, &
Anderson, 2009). Independence was confirmed using Durbin-Watson statistic test (range 2-4).
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R/P (residual/predicted) plots were plotted to evaluate homoscedasticity. Normality check was
performed by plotting histograms. Additionally, a diagnostic test for outliers was assessed using
Mahalanobis distance. Finally, multicollinearity was examined by calculating variance inflation
factor (VIF; larger than 10) and tolerance (less than 0.10) for each predictor. Four separate
hierarchical regressions were run with physical health, psychological health, social relationships
and environmental domain scores as dependent variables. In step one, autism severity was
added. In step two, coping, functional independence and social support were added. Regression
analyses were conducted using SPSS version 22.0 (IBM Corporation, Armonk, NY, US).
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RESULTS
Descriptive statistics
Table 3.1 depicts descriptive statistics for demographic variables. A total of 290 responses were
received. 25 responses were excluded due to missing data (≥20%). A final sample of 265
responses was included for study analysis. The mean age of the adults with autism was ~33
(±13.8) years (range: 18-72 years). Majority of the participants were male (55.7%), white
(82.6%) and were living with their family (45.3%). About 60% of study participants had a
diagnosis of Asperger’s syndrome and were not married at the time the survey was conducted.
The participants also reported having comorbid mental (48.1%) and physical (40.9%) illness
other than autism. The mean score of physical health was 58.90 (±18.26), psychological health
was 54.59 (±16.98), social relationships was 48.26 (±23.29), and environment domain was 58.12
(±17.96), respectively (Table 3.2).

Table 3.1: Study characteristics
Characteristic
Age (in years), means (range); ±SD
Age when diagnosed with autism, means (range); ±SD
Gender
Male
Female
Ethnicity
White
Other
Insurance status
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N
%
33.08 (18-72) ±13.76
22.03 (1-68) ±16.89
147
115

55.7
43.6

218
46

82.6
17.4

Public insurance
Private including HMO
No insurance
Residential Status
Living independently
Living with a partner
Living with family
Living in a supported home (group home)
Occupation
Employed/Self-employed full-time
Employed part-time
Student
Seeking work
Other¥
Education level
Less than high school
High school graduate
Some college or technical school
College graduate or graduate school
Marital status
Never Married
Married
Divorced/Separated/widowed
Not married, living with partner
Primary diagnosis
Classic autism/autistic disorder
Asperger’s syndrome
Pervasive developmental disorder not otherwise specified
Other physical illness (yes)
Other mental illness (yes)
Prescription medications (yes)
Autism-related treatment (yes)
Behavioral therapy (yes)
Occupational therapy (yes)
Recreational therapy (yes)
Physical therapy (yes)
Other therapy (yes)
Seek Assistance to complete the survey
Total
¥
Other included disabled, unemployed, volunteer, etc
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112
120
30

42.4
45.5
11.4

77
55
120
10

29.2
20.8
45.5
3.8

62
39
54
39
70

23.5
14.8
20.5
14.8
26.5

16
44
103
100

6.1
16.7
39
37.9

168
53
25
18

63.6
20.1
9.5
6.8

59
166
35
108
127
152
81
45
27
15
17
34
43
264

22.3
62.9
13.3
40.9
48.1
57.6
30.7
17
10.2
5.7
6.4
12.9
16.3
100

Table 3.2: Study measure descriptive
N
Mean
Possible range Minimum Maximum
264 58.90 (18.26)
0-100
10.71
100.00
Physical health
264 54.59 (16.98)
0-100
0.00
95.83
Psychological health
264 48.26 (23.29)
0-100
0.00
100.00
Social relationships
264 58.12 (17.96)
0-100
15.63
100.00
Environment
259 6.61 (2.29)
1-10
1.00
10.00
Autism severity
262 39.03 (7.81)
16-64
16.00
60.00
Adaptive coping
262 21.14 (5.51)
10-40
10.00
37.00
Maladaptive coping
17-51
17.00
48.00
Functional independence 256 23.88 (7.07)
264 31.66 (7.74)
16-48
12.00
48.00
Social Support

Correlations between study variables
Table 3.3 shows the correlation results between study measures. Autism severity was negatively
correlated with psychological health among adults with autism (r=-0.154; p<0.01). Adaptive
coping was positively correlated with psychological health (r=0.311; p<0.01), social
relationships (r=0.357; p<0.01) and environmental (r=0.152; p<0.01) domain, respectively. A
negative relationship between maladaptive coping with all the WHOQOL-BREF domains was
observed (r=-0.275 – -0.350; p<0.01). Participants with low functional independence had
significantly lower scores for physical health (r=-0.394; p<0.01), physiological health (r=-0.227;
p<0.01), social relationships (r=-0.182; p<0.01) and environment (r=-0.327; p<0.01). Higher
score for social support was associated with higher scores for physical health (r=0.391; p<0.01),
psychological health (r=0.474; p<0.01), social relationships (r=0.511; p<0.01) and environment
(r=0.518; p<0.01).
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Table 3.3: Correlations between study variables
Physical
health
-0.116
0.115
-.0311**

Autism severity
Adaptive coping
Maladaptive coping
Functional
-.0394**
independence
Social support
0.391**
*p<0.05; **p<0.01
Bold indicates non-significant results

QOL Domains
Psychological
Social
health
relationships
-0.154*
-0.047
0.311**
0.357**
-0.348**
-0.275**

Environment
-0.113
0.152*
-0.350**

-0.227**

-0.182**

-0.327**

0.474**

0.511**

0.518**

Predictors of QOL
Structural equation modeling results
Figure 3.2 depicts the modified Wilson and Cleary’s model tested in the study. Model fit indices
indicated poor fit of the modified model with the data (Chi-square[df] =97.13[18], p<0.05; GFI
=0.918; CFI =0.889; RMSEA =0.13; AIC =151.13). Based on modification indices,
improvements were made to the original hypothesized study model. The non-significant paths
between autism severity and adaptive coping and social support and functional independence
were deleted (Figure 3.2; dotted arrows). The model fit improved marginally compared to the
original model (Chi-square [df] =99.302[20], p<0.05; GFI =0.917; CFI =0.888; RMSEA =0.126;
AIC =149.302). Two covariance were specified as free parameters (adaptive and maladaptive
coping and physical and social relationships). The final model had good fit with the data (Chisquare [df] =64.386[18], p<0.05; GFI =0.947; CFI =0.935; RMSEA = 0.1; AIC=118.386). Chisquare difference test revealed the final model fit to be better than the previous model (χ2
difference=34.92; df=2; p<0.001). The final model explained 56.3%, 63.2%, 45.2% and 58.7%
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of variance in physical health, psychological health, social relationships and environmental
domains, respectively.

Figure 3.2: Final quality of life study model based on structural equation modeling. Goodnessof-fit indices for the above model (Chi-square = 64.39 (P<0.001); Chi-square/df = 3.57; GFI =
0.95; CFI = 0.94; AGFI = 0.87; RMSEA = 0.1 [90% CI 0.076, 0.129]). Dotted line represents
direct non-significant relationships. Solid line represents significant relationships.

The significant direct, indirect and total effects of study variables on QOL results are
presented in Table 3.4. As hypothesized, all study variables had a significant (p<0.05) direct
effect on QOL. Autism severity had a direct negative (standardized direct effect regression
weight =-0.165) as well as indirect positive effect (standardized indirect effect regression weight
= 0.059) on QOL through maladaptive coping, functional independence and social support.
Autism severity had a negative effect on social support (standardized direct effect regression
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weight = -0.136), functional independence (standardized direct effect regression weight = 0.189) and maladaptive coping (standardized direct effect regression weight = -0.126). There
was a direct significant positive relationship between social support and QOL (standardized
direct effect regression weight = 0.43). We also found that the relationship between adaptive and
maladaptive coping with QOL was mediated by social support. Maladaptive coping had a direct
negative effect (standardized direct effect regression weight = -0.305) and adaptive coping had a
direct positive effect (standardized direct effect regression weight = 0.259) on QOL. Finally,
higher functional dependence was associated with better QOL (standardized direct effect
regression weight = -0.237).

Table 3.4: Standardized total, direct and indirect effects
Total
effect
Autism severity to maladaptive coping
-0.126
Autism severity to social support
-0.079
Autism severity to functional independence
-0.231
Autism severity to quality of life
-0.106
Adaptive coping to social support
0.329
Adaptive coping to functional independence
-0.162
Adaptive coping to quality of life
0.439
Maladaptive coping to social support
-0.458
Maladaptive coping to functional independence
0.334
Maladaptive coping to quality of life
-0.581
Functional independence to quality of life
-0.237
Social support to quality of life
0.43
Only significant relationships (p<0.05) are shown in the table
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Direct
effect
-0.126
-0.136
-0.189
-0.165
0.329
-0.162
0.259
-0.458
0.334
-0.305
-0.237
0.43

Indirect
effect
0.058
-0.042
0.059

0.18

-0.276

Hierarchical linear regression results
Table 3.5 shows the results for hierarchical linear regression to investigate the ability of autism
severity, coping and social support in predicting QOL. Four separate regressions were
conducted with physical health, psychological health, social relationships and environment as
dependent variables of interest, respectively. There were no violations of the assumption of
normality, linearity, and homoscedasticity. For all models, autism severity was added in step I,
followed by adaptive coping, maladaptive coping, social support and functional independence in
step II.
For physical health, autism severity was not significant in step I. After adding other
mediators in step II, the total variance explained by the model as a whole was 32.8% (p<0.001).
All the variables except adaptive coping were statistically significant. With increase in social
support (β = 0.64; p<0.001) there was a significant increase in physical health among adults with
autism, after controlling for other variables. Significant inverse relationship was observed
between physical health and autism severity (β = -1.34; p<0.05), maladaptive coping (β = -0.52;
p<0.05) and functional independence (β = -0.87; p<0.001). For psychological health, step I
model was statistically significant (β = -1.06; p<0.05) and autism severity explained 2% of
variance for psychological health. Addition of adaptive coping, maladaptive coping, social
support and functional independence significantly increased the variance explained in
psychological health by 36.4% (p<0.001). Social support and adaptive coping had a positive
relationship with psychological health, with greater social support (β = 0.61; p<0.001) and better
adaptive coping strategies (β = 0.66; p<0.001) leading to better psychological health. Increase in
maladaptive coping strategies (β = -1.02; p<0.001) and autism severity (β = -1.17; p<0.05) were
associated with lower psychological health among adults with autism. For social relationships
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and environmental domains, the inclusion of autism severity in step I of the regression analyses
was not statistically significant. However, the potential mediators in step II explained an
additional 36.8% of variance in social relationships and 38.3% of variance in environmental
domain of QOL. Increase in social support (β = 1.06; p<0.001) and adaptive coping strategies (β
= 1.02; p<0.001) and decrease in maladaptive coping strategies (β = -1.04; p<0.05) resulted in
better social relationships. For environmental domain, autism severity (β = -1.05; p<0.05),
social support (β = 0.99; p<0.001), maladaptive coping (β = -0.59; p<0.05) and functional
independence (β = -0.57; p<0.001) emerged as the significant predictors.

Table 3.5: Predictors of quality of life domains
Physical
health
β (SE)

Quality of life domains
Psychological
Social
health
relationship
β (SE)
β (SE)

Step 1
Autism severity
-0.81 (0.49)
-1.06* (0.46)
2
0.011
0.021
R
2
0.007
0.017
Adjusted R
Step 2
Autism severity
-1.34* (0.43)
-1.17* (0.46)
Adaptive coping
0.17 (0.14)
0.66** (0.12)
Maladaptive coping
-0.52* (0.21) -1.02** (0.19)
Functional independence -0.87** (0.15)
-0.22 (0.13)
Social support
0.64** (0.14)
0.61** (0.13)
2
0.328
0.381
R
2
0.321
0.364
R change
2
0.315
0.368
Adjusted R
**p<0.001; *p<0.05
P values were based on hierarchical linear regression
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Environment
β (SE)

-0.36 (0.64)
0.001
-0.003

-0.82 (0.50)
0.011
0.007

-0.14 (0.54)
1.02** (0.17)
-1.04* (0.27)
-0.07 (0.18)
1.06** (0.18)
0.369
0.368
0.356

-1.05* (0.41)
0.18 (0.13)
-0.59* (0.20)
-0.57** (0.14)
0.99** (0.14)
0.390
0.383
0.378

DISCUSSION
In the present cross-sectional study, QOL among adults with autism was studied using a
modified Wilson and Cleary’s model. To the best of our knowledge, this is the first study to
assess QOL among adults with autism in the US. Studies in the past have reported lower QOL
among adults with autism; however, the factors influencing QOL have been sparsely reported.
The relationship between constructs including autism severity, social support, adaptive and
maladaptive coping and functional independence and QOL was examined in this study.
Results from the SEM analysis demonstrated a direct and an indirect association of
autism severity with QOL. As was hypothesized, adults with severe autism were found to have
lower QOL. Prior studies have reported mixed results regarding the relationship between autism
severity and QOL (Kamio, et al., 2013; Kamp-Becker, et al., 2010; Renty & Roeyers, 2006).
Kamio et al. (2013) found a negative relationship between aggressive behavior and social
relationship domain of QOL among adults with autism in Japan. In contrast, Renty and Roeyers
(2006) and Kamp-Becker et al. (2010) found no relationship between autism severity and QOL
among adults with autism in Belgium and Germany, respectively. Lack of significant
association in these studies may be attributable to their low sample sizes. A recent study by
Khanna et al. (2014) reported a small negative correlation between autism severity and both
physical and mental health domains of HRQOL in a sizable sample of adults with autism in the
US. Our results indicate that autism severity may have an influence on QOL among adults with
the disorder. Considering the limitations imposed by autism, it reasonable to expect variation in
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QOL by severity of the disorder. With respect to individual domains of QOL instrument, we
found that an increase in autism severity was associated with a decrease in physical health,
psychological health and environmental QOL. As hypothesized, the relationship between autism
severity and QOL was found to be mediated by modifiable variables such as maladaptive coping,
functional independence and perceived social support. The impact of autism severity on QOL
may alleviate if there is restricted use of maladaptive coping behaviors. Family members and
clinicians could assist adults with autism in developing better coping mechanisms, which can
help adults in the long-term management of symptoms and potentially improve their QOL.
Alternatively, better perceived social support seems to lessen the negative impact of autism
severity on QOL. Better social support from friends and family can help improve some of the
symptoms such as communication skills and social engagement resulting in better QOL.
Functional independence was found to attenuate the direct path between autism severity and
QOL. Greater social support and the ability to perform activities of daily living may not only
alleviate the impact of autism severity on QOL, but may also help these adults develop
confidence in their ability to manage the symptoms associated with this disorder.
The role of coping on QOL is an understudied area among adults with autism. Only one
study among adults with autism has studied the relationship between coping and HRQOL among
adults with autism (Khanna, et al., 2014). The authors of the study reported a negative
relationship between maladaptive coping and both physical and mental health among adults with
autism. Negative relationship between maladaptive coping and all four domains of QOL was
also observed in this study. Khanna et al. (2014) found no significant relationship between
adaptive coping and physical and mental health in their study. We also found a direct effect of
adaptive coping on QOL in our study. In their examination of coping and HRQOL, Khanna et
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al. (2014) found no relationship between the two constructs. It should be noted that in regression
analysis, we only found partial support for the link between adaptive coping and QOL, with
adaptive coping being positively related to psychological and environmental health, but not with
physical health and social relationships. Our results together with those reported by Khanna et
al. (2014) reflect that adaptive coping may have an influence on psychological health and nonhealth related domains of QOL. Using adaptive coping to deal with a disorder like autism is less
likely to bring any physical health benefits, which may explain the lack of relationship between
the two constructs. Rather, positive coping techniques including positive reframing, planning,
acceptance and active coping may help improve mental health of adults with the disorder. Social
support and functional independence were found to mediate the relationship between adaptive
and maladaptive coping and QOL in this study. Perceived social support can lead to better QOL
by alleviating the effect of maladaptive coping (negative behavior) and ameliorating the effect of
adaptive coping (positive behavior) among adults with autism. Together, these results highlight
the critical role played by social support and coping in influencing the QOL of adults with
autism.
A direct relationship between functional independence and QOL was observed in this
study. An increase in functional independence was found to be associated with better physical
and environmental QOL. Studies in other disease areas have reported that satisfaction with daily
activities can lead to better QOL (Eklund, 2009). It has been suggested that more than a real
world job, meaningful daily activities have better opportunity to improve QOL among
individuals with mental illnesses. The ability to perform everyday activities satisfactorily may
make individuals with mental illnesses feel more capable. As individuals with autism age, it is
essential that proper training and interventions aimed at teaching them functional skills be
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provided with a goal of helping them become functionally independent. This may help them
better perform their day-to-day activities, which may eventually translate into an improved QOL.
Our results suggest that perceived social support plays an important role in improving
QOL among adults with autism in the US. The association between perceived social support and
QOL is well documented in the literature (Burgess & Gutstein, 2007; Kamio, et al., 2013;
Khanna, et al., 2014; Renty & Roeyers, 2006; Seltzer, et al., 2004). Consistent with these past
studies, we found perceived social support as a key positive predictor of QOL among adults with
autism. Studies in the past have consistently reported unmet need in the social arena among
adults with autism (Eaves & Ho, 2008; Lasgaard, Nielsen, Eriksen, & Goossens, 2010). Billstedt
and researchers (2011) described the importance of suitable environment and community support
among young adults with autism who are still dependent on their caretakers for activities such as
education, occupation and residence. Perceived social support from siblings, friends and parents
can also help in reducing loneliness among adults with autism (Lasgaard, et al., 2010). Renty
and Roeyers, (2006) found perceived informal social support as a significant predictor of QOL
among adults with high-functioning autism (HFA). In our study, perceived social support was
found to have a positive influence on all of the individual domains of QOL (physical health,
psychological health, social relationships and environment). Having social support may help
adults with autism feel more acceptable and valued by their family members, friends, and the
overall society.
We found the modified Wilson and Cleary’s QOL conceptual model to work well in
explaining the QOL of adults with autism in this study. This study represents a first step in
identifying modifiable factors such as autism severity, social support, functional independence
and coping as significant predictors of QOL. Unlike other studies in the past, the use of SEM
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methodology allowed us to test several different relationships of key study variables (autism
severity, social support, coping and functional independence) on the latent QOL variable in this
study. Future research in this area could incorporate additional individual and environmental
factors such as employment, role of comorbidites especially anxiety and depression levels,
parental factors and others to study their influence on QOL of adults with autism. For example,
anxiety and depression are the most common psychiatric co-occurring conditions among adults
with autism (Boyd, Woodbury-Smith, & Szatmari, 2011; Gillott & Standen, 2007; Joshi et al.,
2013; Mazzone et al., 2013). Understanding the role of such comorbid conditions and its
influence on QOL may help identify additional approaches to improve overall health and QOL
among adults with autism.
Limitations
A few limitations must be considered while interpreting the results of this study. The sample of
this study consisted of adults with autism enrolled with IAN who had the intellectual capacity to
self-report on the study questionnaire with little or no help from their caregivers. Around 63% of
our study participants had a diagnosis of Asperger’s syndrome, suggesting an over representation
of adults with Asperger syndrome. Together these factors could restrict the generalizability of
study findings. Causal relationships among study variables cannot be assumed considering the
cross-sectional design used for the study. Future studies could conduct use a longitudinal design
to establish more robust evidence of the predictive relationships between the variables to
investigate change in perceived social support, maladaptive coping, adaptive coping, functional
independence and autism severity and their association with QOL.
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Conclusion
The current study builds on the literature on QOL among adults with autism. By using a wellvalidated theoretical framework, this study provides information on the factors interacting with
QOL of adults with autism. The modified Wilson and Cleary’s QOL conceptual model worked
well in the study. Study results highlighted the key role played by autism severity, adaptive
coping, maladaptive coping, functional independence and perceived social support in influencing
QOL of adults with autism. Social support was found to have a positive influence on QOL.
Further, social support was found to mediate the impact of coping on QOL. Stakeholders
(caregivers, providers, and policy makers) involved in the provision of care to adults with autism
must consider the role of support in improving the overall well-being of these individuals. Our
results suggest that better coping strategies and more functional independence can improve QOL
among adults with autism. The fact that these variables are modifiable could work as an
advantage for stakeholders in improving the QOL of adults with autism. Whether it is through
daily interaction with family members and friends, clinic visit with provider, or health-based
interventions, there should be an effort made towards improving the QOL of adults with autism
through these generally modifiable approaches.
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APPENDIX A: REVIEW OF QUALITY OF LIFE STUDIES AMONG ADULTS WITH AUTISM
Authors

Questionnaire

Adult and Adolescent PsychoPersson, 2000
Educational Profile (AAPEP)
JennesCoussens et
al., 2006
Renty and
Roeyers,
2006
Gerber et al.,
2008
87

Eaves and
Ho, 2008

World Health Organization
QOL-Brief (WHOQOL-BREF)
QOL questionnaire (QOL.Q)
Inventaire de Qualite´ de Vie en
Milieu Re´sidentiel’’
(I.Q.V.M.R.)
Global rating (Overall Outcome
Rating, OOR) of very good to
very poor outcome

Proxy-reported or selfreported HRQOL
Questionnaire-Direct
observation as well as
staff-reported
Self-administered
questionnaire as well as
semi-structured interview
Self-administered
questionnaire as well as
semi-structured interview
Proxy-reported
questionnaire
Proxy-reported (parents
reported) questionnaire

KampBecker et al.,
2010

WHOQOL-BREF

Paper-based self-reported
questionnaire

Billstedt et
al., 2011

QOL measure I and II (QOL I
and II)

Proxy-reported (staffreported) questionnaire

Kamio et al.,
2013

WHOQOL-BREF

Paper-based self-reported
questionnaire

Cottenceau
et al., 2012
Khanna et
al., 2014

Vécu et Santé Perçue de
l'Adolescent (VSP-A)
Short Form 12 item version 2
(SF12v2) Health Survey

Paper-based self-reported
questionnaire
Internet-based selfreported

Sample and Sample size
7 adults with autism
Mean age: 32.3 years (range 20-50
years)
12 adults with Asperger’s syndrome
Mean age: 20.3 years (range 18-21
years)
58 adults with autism
Mean age: 28.34 years (range 18-53
years)
30 adults with autism
Mean age: 39.9 years (range 24-62
years)
48 adults with autism
Mean age: 24 years (range 19-31 years)
26 adults with autism
Mean age: 21.6 years (range 17-28
years)
108 adults with autism
Mean age: 25.5 years (range 17-40
years)
154 adults with high functioning autism
Mean age: 27.6 years (range 18-49
years)
26 adolescents with autism
Mean age: 15 years (range 10-19 years)
291 adults with autism
Mean age: 31 years (range 18–65years)

Country
Sweden

Canada

Belgium

Switzerland

Canada

Germany

Sweden

Japan
France
United
States

APPENDIX B: LETTER FROM INTERACTIVE AUTISM NETWORK
February 11, 2013
Ms. Krutika Jariwala
Department of Pharmacy Administration
University of Mississippi
School of Pharmacy
238 Faser Hall
University, MS 38677

Dear Ms. Jariwala,
re: IAN (Interactive Autism Network) Project Subject Recruitment Support for
Quality of life and healthcare utilization and cost among adults with autism
(IAN Application SR00560)
The IAN Project would like to offer its support for the above study and your application for a 2013
Organization for Autism Research (OAR) Graduate Research Grant. The IAN Project is an innovative
online project designed to accelerate the pace of autism research by linking researchers and families.
The IAN Project consists of two primary areas:
IAN Research is an autism-focused longitudinal database and research registry designed to
facilitate research efforts. Families impacted by an Autism Spectrum Disorder (ASD) share their
information via the internet from the comfort of home, while researchers apply to access data or to
recruit research participants. IAN Research is governed by the Johns Hopkins Medicine IRB
(NA_00002750; PI Dr. Paul Law).
IAN Community is a website and meeting place where all concerned with ASDs can gather to
learn about autism research, view up-to-date IAN Research findings, and provide input into the
research process.
IAN helps researchers with recruitment in two ways: by informing our participants about studies for
which they qualify via email and by posting information about such studies on the IAN Community
Research Opportunities Bulletin Board. To date IAN has provided recruitment and/or data services for
more than 400 research studies.
Since the launch of the project in April 2007, IAN Research has consented more 43,000 participants,
including more than 15,000 children and young adults with ASD. There are currently approximately
3,000 consented individuals with ASD who are aged 18 years or older in IAN Research.
Approximately, 1,000 of these have Autistic Disorder, and 2,000 have Asperger’s Syndrome, PPDNOS, or other ASD diagnosis. This represents the current participant pool for your study. Please note
that over the course of your study, participants consented as children will become adults and will, thus,
become eligible for the study. (We are permitted to contact the parents to let them know about your
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Kennedy Krieger Institute / Department of Medical Informatics / 3825 Greensping Avenue, 1 Floor / Baltimore, MD 21211
tel 443-923-4140
www.IANproject.org
443-923-4145 fax
A web project of Kennedy Krieger Institute ∙ Sponsored by Autism Speaks, the Simons Foundation, and the NIMH

study because they, too, are consented participants). In addition, participants will join IAN
Research and may become eligible for your study.
IAN services will include: assistance with the development of the IAN subject recruitment
letter for your study; selection of potentially eligible IAN participants for your study; emailing
the IAN subject recruitment letter to the parents of potentially eligible IAN research
participants, including a follow-up reminder email; and general assistance with IAN Subject
Recruitment application. In addition, your study will be posted on the IAN Community
Research Opportunities Bulletin Board, if necessary. For these services, IAN’s estimated
subject recruitment cost recovery fee will be $2,000.
We at the IAN Project look forward to working with you on this study.

J. Kiely Law, MD, MPH
Research Director, IAN Project
Project lawk@kennedykrieger.org
443-923-4142

Alison R. Marvin, PhD
Research Coordinator/Data Manager, IAN
marvin@kennedykrieger.org
443-923-4143
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APPENDIX C: COVER LETTER

IAN Subject Recruitment Sample Letter for Researcher Submission to the IRB
Dear IAN Research Participant,
When you joined the Interactive Autism Network (IAN Research Project), we promised to
inform you about research projects that might be of interest to you. Below is an invitation from a
team of researchers seeking IAN Research Project participants to join a new study. If you or a
family member thinks that they qualify for this study and are interested in joining, please click
on the study link or contact the study team directly using the information provided.
You do not have to participate in this study and your non-participation will neither affect the care
you receive from any health provider nor your standing as a participant in IAN Research.
Please note that IAN Research is serving as a resource linking the autism community and
researchers. This study is not endorsed by or performed under the auspices of the IAN Research
project at Kennedy Krieger Institute/Johns Hopkins.
Name of Study: Quality Of Life and Healthcare Utilization and Costs among Adults with
Autism Spectrum Disorder
Institution: University of Mississippi, School of Pharmacy
Location: Web-based study; no geographic limitation within the United States
Eligibility Criteria: Adults with autism spectrum disorder (ASD) or Asperger’s syndrome (AS)
residing in the United States who are:
 greater than or equal to 18 years of age and
 able to self-report the questionnaire with little or no proxy help
Principal Investigator: Rahul Khanna, MBA, Ph.D., Assistant Professor
Contact Information: Krutika Jariwala at kjariwal@go.olemiss.edu or Dr. Khanna at 1-662915-1651
Study Link: http://uofmississippi.qualtrics.com/SE/?SID=SV_3OEKvgYoSOj8L9b
Dear IAN Research Participant,
We would like to invite you to participate in an online research study aimed at assessing the
quality of life among adults with autism. If you have already completed and submitted the
survey, we thank you for your time and participation. If you have not completed the survey, we
request you to kindly do so. Survey respondents should be adults with ASD/AS who are able
to complete the questionnaire independently or with minimal outside assistance.
The online survey should take less than 10 minutes to complete. You should take this survey in
one sitting to ensure that your answers are recorded. Participation in this study is voluntary and
you do not have to answer questions with which you are not comfortable.
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As a token of our appreciation, we will email you a $5 Amazon gift code for your participation.
We will need you to provide your email address in order to send you the gift code. Your email
address will not be associated with your responses, and your responses will remain confidential.
You may choose not to provide your email address; however, we will not be able to send you
your gift code without it. The gift code will be emailed within 2 to 4 weeks of receiving your
completed response. We will send you the results of the study if we have your email address.
To join this study, click the following link:
http://uofmississippi.qualtrics.com/SE/?SID=SV_3OEKvgYoSOj8L9b
(This is the same link as the one listed in the summary information above, so you can click either
one).
This study has been reviewed by The University of Mississippi’s Institutional Review Board
(IRB). The IRB has determined that this study fulfills the human research subject protections
obligations required by state and federal law and University policies. If you have any questions,
concerns, or reports regarding your rights as a participant of research, please contact the IRB at
1-662-915-7482.
We thank you in advance for your time and contribution in providing us with this valuable
information. If you have questions or need more information, please do not hesitate to contact
Krutika Jariwala at kjariwal@go.olemiss.edu or Dr. Khanna at 1-662-915-1651.
Warm Regards,
Dr. Rahul Khanna, M.B.A., Ph.D.
Krutika Jariwala, M.S.
Note:
IAN Research ID SR00560; the Interactive Autism Network research team can be reached at
researchteam@IANproject.org
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APPENDIX D: SURVEY INSTRUMENT

Survey Instrument – 1
NOTE: The survey should be completed by adults who have been diagnosed with autism spectrum
disorder.
There are no right or wrong answers.

The survey has two sections:
Section I
Part I - Health and Well-Being (World Health Organization Quality of Life-Brief [WHOQOL-BREF])
Part II - Coping Strategies (Brief Coping Orientation to Problem Experiences [BRIEF-COPE])
Part III - Social Support (Interpersonal Support Evaluation List [ISEL]-12)
Part IV - Autism Severity (Autism Spectrum Quotient [AQ]-10)
Part V - Functional Independence (Activities of Daily Living [ADL])
Section II
Part I: Socio-demographics and medical history variables
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Section I: Part I - Health and Well-Being

Instructions:
This assessment asks how you feel about your quality of life, health, or other areas of your life.
Please answer all the questions. If you are unsure about which response to give to a question, please
choose the one that appears most appropriate. This can often be your first response.
Please keep in mind your standards, hopes, pleasures and concerns. We ask that you think about your
life in the last two weeks. For example, thinking about the last two weeks, a question might ask:

The following questions ask about how much you have experienced certain things in the last two
weeks.
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The following questions ask about how completely you experience or were able to do certain things
in the last two weeks.

The following questions ask you to say how good or satisfied you have felt about various aspects of your
life over the last two weeks.

your abilities?
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your mode of transport?

The following question refers to how often you have felt or experienced certain things in the last two
weeks.

Murphy, B., Herrman, H., Hawthorne, G., Pinzone, T., Evert, H. (2000). Australian WHOQoL instruments:
User’s manual and interpretation guide. Australian WHOQoL Field Study Centre, Melbourne, Australia.
World Health Organization (1993). WHOQoL Study Protocol. WHO (MNH7PSF/93.9).
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Section I: Part II - Coping
INSTRUCTIONS:
These items deal with ways you've been coping with the stress in your life since you realized you have autism.
Different people deal with things in different ways, but we are interested in how you've tried to deal with it.
Each item says something about a particular way of coping. We want to know to what extent you've been doing
what the item says. Don't answer on the basis of whether it seems to be working or not—just whether or not
you're doing it. Use these response choices, please select your response for each question.

1 = I haven’t been doing this at all
2 = I’ve been doing this a little bit
3 = I’ve been doing this a medium amount
4 = I’ve been doing this a lot
1

I've been turning to work or other activities to take my mind off things.

1

2

3

4

2

I've been concentrating my efforts on doing something about the situation I'm
in.

1

2

3

4

3

I've been saying to myself "this isn't real".

1

2

3

4

4

I've been getting emotional support from others.

1

2

3

4

5

I've been giving up trying to deal with it.

1

2

3

4

6

I've been taking action to try to make the situation better.

1

2

3

4

7

I've been refusing to believe that it has happened.

1

2

3

4

8

I've been saying things to let my unpleasant feelings escape.

1

2

3

4

9

I’ve been getting help and advice from other people.

1

2

3

4

10

I've been trying to see it in a different light, to make it seem more positive.

1

2

3

4

11

I’ve been criticizing myself.

1

2

3

4

12

I've been trying to come up with a strategy about what to do.

1

2

3

4

13

I've been getting comfort and understanding from someone.

1

2

3

4

14

I've been giving up the attempt to cope.

1

2

3

4

15

I've been looking for something good in what is happening.

1

2

3

4

16

I've been making jokes about it.

1

2

3

4

17

I've been doing something to think about it less, such as going to movies,
watching TV, reading, daydreaming, sleeping, or shopping.

1

2

3

4

18

I've been accepting the reality of the fact that it has happened.

1

2

3

4

19

I've been expressing my negative feelings.

1

2

3

4
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20

I've been trying to find comfort in my religion or spiritual beliefs.

1

2

3

4

21

I’ve been trying to get advice or help from other people about what to do.

1

2

3

4

22

I've been learning to live with it.

1

2

3

4

23

I've been thinking hard about what steps to take.

1

2

3

4

24

I’ve been blaming myself for things that happened.

1

2

3

4

25

I've been praying or meditating.

1

2

3

4

26

I've been making fun of the situation.

1

2

3

4

Carver, C. S. (1997). You want to measure coping but your protocol’s too long: Consider the Brief
COPE. International Journal of Behavioral Medicine, 4, 92-100.
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Section I: Part III - Social Support
INSTRUCTIONS
This scale is made up of a list of statements each of which may or may not be true about you. For each
statement select "definitely true" if you are sure it is true about you and "probably true" if you think it is true but
are not absolutely certain. Similarly, you should select "definitely false" if you are sure the statement is false
and "probably false" if you think it is false but are not absolutely certain.
1. If I wanted to go on a trip for a day (for example, to the country or mountains), I would have a hard time
finding someone to go with me.
1. definitely false
2. probably false
3. probably true
4. definitely true
2. I feel that there is no one I can share my most private worries and fears with.
1. definitely false
2. probably false
3. probably true
4. definitely true
3. If I were sick, I could easily find someone to help me with my daily chores.
1. definitely false
2. probably false
3. probably true
4. definitely true
4. There is someone I can turn to for advice about handling problems with my family.
1. definitely false
2. probably false
3. probably true
4. definitely true
5. If I decide one afternoon that I would like to go to a movie that evening, I could easily find someone to go
with me.
1. definitely false
2. probably false
3. probably true
4. definitely true
6. When I need suggestions on how to deal with a personal problem, I know someone I can turn to.
1. definitely false
2. probably false
3. probably true
4. definitely true
7. I don't often get invited to do things with others.
1. definitely false
2. probably false
3. probably true

4. definitely true

8. If I had to go out of town for a few weeks, it would be difficult to find someone who would look after my
house or apartment (the plants, pets, garden, etc.).
1. definitely false
2. probably false
3. probably true
4. definitely true
9. If I wanted to have lunch with someone, I could easily find someone to join me.
1. definitely false
2. probably false
3. probably true
4. definitely true
10. If I was stranded 10 miles from home, there is someone I could call who could come and get me.
1. definitely false
2. probably false
3. probably true
4. definitely true
11. If a family crisis arose, it would be difficult to find someone who could give me good advice about how to
handle it.
1. definitely false
2. probably false
3. probably true
4. definitely true
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12. If I needed some help in moving to a new house or apartment, I would have a hard time finding someone to
help me.
1. definitely false
2. probably false
3. probably true
4. definitely true

Cohen, S., Hoberman, H. M. (1983). Positive events and social supports as buffers of life change stress.
Journal of Applied Social Psychology,13:99–125.
Cohen, S., Mermelstein, R., Kamarck, T., Hoberman, H. (1985). Measuring the functional components of
social support. In: Sarason IG, Sarason BR, editors. Social Support: Theory, Research and Application.
The Hague, Holland: Martinus Nijhoff.
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Section I: Part IV- Autism Severity

Please select one option per question only:
Definitely
Agree

Slightly
Agree

Slightly
Disagree

Definitely
Disagree

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1.
2.

I often notice small sounds when others do not.
I usually concentrate more on the whole
picture, rather than the small details.
3. I find it easy to do more than one thing at once
4. If there is an interruption, I can switch back to
what I was doing very quickly.
5. I find it easy to ‘read between the lines’ when
someone is talking to me.
6. I know how to tell if someone listening to me is
getting bored.
7. When I’m reading a story I find it difficult to
work out the characters’ intentions.
8. I like to collect information about categories of
things (e.g. types of car, types of bird, types of
train, types of plant etc).
9. I find it easy to work out what someone is
thinking or feeling just by looking at their face
10. I find it difficult to work out people’s intention

Allison, C., Auyeung, B., Baron-Cohen, S. (2012) Journal of the American Academy of Child and
Adolescent Psychiatry, 51(2):202-12.
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Section I: Part V - Functional Independence
Instructions: “We would like to know about your current level of independence in performing activities of
daily living. For each activity please select the option which best describes your ability to do the task. For
example, Independent would mean you are able to do the task without any help or assistance”

PLEASE RATE YOUR’S LEVEL OF INDEPENDENCE IN...

Ability to perform task
2=
1 = does
0 = does
Independent or
with
not do at
does on own
help
all

1. Making your own bed
2. Doing household tasks, including picking up around the house,
putting things away, light housecleaning, etc.
3. Doing errands, including shopping in stores
4. Doing home repairs, including simple repairs around the house,
non-technical in nature; for example, changing light bulbs or
repairing a loose screw
5. Doing laundry, washing and drying
6. Washing/bathing
7. Grooming, brushing teeth, combing and/or brushing hair
8. Dressing and undressing
9. Toileting
10. Preparing simple foods requiring no mixing or cooking, including
sandwiches, cold cereal, etc.
11. Mixing and cooking simple foods, fry eggs, make pancakes, heat
food in microwave, etc.
12. Preparing complete meal
13. Setting and clearing table
14. Drinking from a cup
15. Eating from a plate
16. Washing dishes (including using a dishwasher)
17. Banking and managing daily finances, including keeping track of
cash, checking account, paying bills, etc. (Note: if you can do a
portion but not all select”does with help”.)

Maenner, M. J., Smith, L. E., Hong, J., Makuch, R., Greenberg, J., Mailick, M. R. (2013) An Evaluation
of an Activities of Daily Living Scale for Adolescents and Adults with Developmental Disabilities.
Disability and Health Journal, 6(1):8-17
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Section II: Part I- This section collects basic socio-demographic and medical history information.
INSTRUCTIONS:
Please answer the following questions to help us better understand your responses.

1. Your age (in YEARS): ______________
2. Are you:  Male

 Female

3. What is your ethnicity? (Please select one, only)
 White
 Black/African-American
 Hispanic/Latino
 American Indian/Alaskan Native
 Asian
 Native Hawaiian/Pacific Islander
 Other (please specify) ______________
4. What kind of primary health care coverage do you have? (Please select one, only)
 Medicare
 Medicaid
 Private including HMO
 No insurance
5. What is your current residential status (Please select one, only):
 Living independently
 Living with a partner
 Living with family
 Living in a supported home (group home)
6. Which of the following describes your main occupation? (Please select one, only)
 Employed/Self-employed full-time  Employed part-time
 Retired
 Student
 Seeking work
 Home-maker
 Other (please specify) _____________________________
7. What is the highest level of education that you have completed? (Please select one, only)
 Less than high school
 High school graduate
 Some college
 Technical school
 College graduate
 Graduate school

8. What is your current marital status? (Please select one, only)
 Never married
 Not married/living with a partner
 Married
 Divorced/separated
 Widowed
9. Please indicate your primary diagnosis? (Please select one, only)
 Classic autism/autistic disorder
 Asperger’s syndrome
 Pervasive developmental disorder not otherwise specified (PDD-NOS)
10. Beside autism, do you have:
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Other physical illness
 Yes (please specify) ______________________

 No

Other mental (not including autism) illness
 Yes (please specify) ______________________

 No

11. Are you currently taking any prescription medications?
 Yes
 No
If yes, please list all the prescription medications you are currently taking.
_____________________________________________________________
_____________________________________________________________
_____________________________________________________________
12. Age (in YEARS) when first diagnosis with autism? _______________
13. Are you currently using or have used in the past one year any autism-related treatment and program
services?
 Yes
 No
If yes, please select all that applies
Behavioral therapy
 Yes
 No
Occupational therapy
 Yes
 No
Recreational therapy
 Yes
 No
Physical therapy
 Yes
 No
Other
 Yes, please specify ______________

 No

14. Did you seek assistance from anyone else (family, friend, etc.) for the purpose of completing this survey?
 Yes
 No
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You will be redirected to a different server in order receive a $5 Amazon gift code. The gift code will be
emailed within 2 to 4 weeks of receiving your completed response.

THANK YOU IN ADVANCE FOR YOUR TIME AND EFFORT!

104

Survey Instrument II:
To receive a $5 Amazon gift code, please provide your email address below:
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CHAPTER 4
PREVALENCE, HEALTHCARE UTILIZATION AND COSTS, AND MEDICATION
USE AMONG ADULTS WITH AUTISM ENROLLED IN THE MEDICAID PROGRAM
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INTRODUCTION
Autism spectrum disorders are neurodevelopmental disorders characterized by repetitive and
restrictive behavior and limited social and communication skills (American Psychiatric
Association, 2000). One in 42 boys and one in 189 girls were diagnosed with autism in the
United States (US) in 2014 (MMWR, 2014). The prevalence data on adults with autism in the
US is not currently available; however, a study conducted in England by Bruga et al. (2011)
reported that the prevalence among adults to be ~1%. Children with autism have higher
healthcare utilization and expenditure in terms of outpatient visits, physician visits, medication
use, emergency department encounters and inpatient hospitalizations compared to children
without autism (Croen, Najjar, Ray, Lotspeich, & Bernal, 2006; Liptak, Stuart, & Auinger,
2006). In the US, the lifetime cost of supporting an adult with autism with intellectual disability
(ID) is around $2.4 million while those without ID was about $1.4 million (Buescher, Cidav,
Knapp, & Mandell, 2014). In addition, the mean annual cost per capita is around ~$88,000
among autistic adults with ID and ~$50,000 among those without ID. Housing, direct medical,
and indirect (loss productivity) constitute the largest proportion of this cost. In general, adults
with autism have been found to have higher medical cost than children with autism (Buescher, et
al., 2014).
A study conducted by Nicolaidis et al. (2012) highlighted several health care disparities
experienced by autistic adults in comparison with adults without autism. The authors reported
that autistic adults are significantly more likely to have unmet needs in mental health, physical
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health and prescription medication areas compared to non-autistic adults. The authors further
reported that compared to adults without autism, adults with autism were less likely to receive
preventive care services such as tetanus vaccination, blood pressure measurement and Pap smear
in the last three years. In terms of healthcare utilization, the authors found that autistic adults
had higher emergency room (ER) visits compared to non-autistic adults. Similar findings were
reported by Iannuzzi et al. (2014) based on their analysis of the 2010 Nationwide Emergency
Department Sample (NEDS) data. Adults with autism were found to have significantly higher
emergency department visits compared to children with autism. In their analysis of the 2003
commercial payer MarketScan data, Shimabukaro et al. (2007) found ~4 times higher cost per
year among privately insured autistic adults (18-21 years) compared to non-autistic adults. The
authors further reported that adults with autism incurred ~$3,930 (~9.3 times higher) of median
healthcare expenditure compared to adults without the disorder.
Studies have reported a high degree of prescription medication use (especially
psychotropic drugs) among adults with autism. A recent study using longitudinal, population
based cohort of adults with autism since 1980’s reported that 59% of adults with autism were
taking some type of psychotropic medication and about 34% had at least one psychiatric
diagnosis during the study period (Buck et al., 2014). In a longitudinal evaluation (4.5 years) of
medication use, Esbensen et al. (2009) reported an increase in psychotropic and nonpsychotropic medication use among adolescents and adults with autism. The authors also found
that out of the total sample, ~81% of adolescents and adults with autism were taking some
medication and ~64% of adolescents and adults were on psychotropic medications. In addition,
~67% of their sample had at least one co-morbid condition. The authors further suggested that
autistic adults and adolescents were more likely to continue their medication use once it was
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initiated. Anti-psychotics and anti-depressants were the most common psychotropic drugs
consumed by adolescents and adults with autism in their study. In another study, Khanna et al.
(2013) utilized 2007 state Medicaid data to study the use and cost of psychotropic medication
among recipients with autism. Adults with autism (≥21 years) were found to have roughly
double the number of psychotropic prescription claims compared to individuals with autism aged
11-21 years (29 vs. 16 average drug claims per recipient).
The data on prevalence and health care utilization and cost among adults with autism
enrolled in Medicaid program is not currently available. Since the Medicaid program primarily
provides health coverage to low income individuals, it is essential to understand the final burden
of autism in this population. The results of the study will help Medicaid state regulators to
understand the economic burden of autism in adults and to provide necessary services and
coverage to these individuals. The specific objectives were: 1) to estimate the trends in autism
prevalence and all-cause medical services and prescription use; and 2) to study the predictors of
medical services utilization and costs among adults with autism enrolled in the Medicaid
program.
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METHODS
Data source and study design
A retrospective descriptive analysis of 2006-2008 Medicaid administrative claims data for 39
states (Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida,
Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts,
Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New
Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Rhode Island, South Carolina,
Tennessee, Texas, Vermont, Virginia, Washington, and West Virginia) was conducted. The
Medicaid Analytic Extract (MAX) data contains, 1) person summary file (demographic
information and eligibility periods for the beneficiaries), 2) pharmacy claims file (medication
related information), 3) other services file (outpatient hospital, physician office, and ER visits),
and 4) inpatient services file (information on admission and discharge dates, diagnoses, and
amount paid). The Center for Pharmaceutical Marketing and Management (CPMM) at the
University of Mississippi already had the data required for this project. In order to protect
privacy of the patients, information on the individual beneficiaries was encrypted with unique
identification numbers where individuals are not identifiable. Study files were linked using the
unique identification number. University of Mississippi Institutional Review Board (UM IRB)
approval was received for the study under exempt status.
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Sample selection
Recipients were eligible for the analysis if they were continuously enrolled in Medicaid
throughout the study period (2006-2008) and if they were aged ≥ 18 years as of January 1, 2006
and < 65 years of age as of December 31, 2008. Recipients with long-term care claims were
excluded due to the possibility of incomplete medication and hospitalization information for such
individuals. Recipients with a diagnosis of autism were identified using International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 299.xx. A
recipient with ≥1 prescription claim for a medication filled to treat autism at any time during the
study year was considered as medication users. Different classes of psychotropic drugs and nonpsychotropic drugs were considered based on prior literature in the area of autism (Esbensen, et
al., 2009; Khanna, et al., 2013). Psychotropic drug classes included in this study were
antipsychotics, antidepressants, stimulants, anxiolytics/hypnotics/sedatives and other
psychotropics (antimanic drugs including lithium, valproic acid, and carbamazepine, memantine,
anticonvulsants and beta blockers).
Measures
Prevalence rates
Prevalence rate among adults with autism was calculated by dividing the number of unique
recipients with primary or secondary diagnosis of autism to the number of Medicaid recipients
meeting the inclusion criteria per year. Rates were stratified based on demographic variables (by
age, race, state, and location of residence) for each calendar year. Prevalence was reported as
cases per 1,000 Medicaid recipients.
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Healthcare utilization and costs
All-cause medical services costs and utilization were computed for all eligible patients for all
three years (2006-2008) individually. The MAX inpatient and other therapy files were used to
identify healthcare utilization and costs. The perspective of Medicaid was used to calculate cost
in this study. The results were further stratified by age, race, and location of residence (rural and
urban). Healthcare utilization and expenditures in terms of physician visits, ER visits, diagnostic
or laboratory tests, hospitalizations (length of stay), outpatient hospital visits and prescription
refills were assessed. Utilization variables, measured as counts of unique visits and
expenditures, were measured by summing all the costs associated with the visits. Rates of
beneficiaries using all-cause outpatient visits, inpatient visits and ER visits were reported as
visits per 10,000 Medicare beneficiaries meeting the inclusion criteria and were stratified for
demographic variables for each calendar year. Psychotropic drug utilization was also reported
for individual drug classes for all three years separately.
Co-morbid conditions
Three measures were coded to control for co-morbid conditions: disease severity (yes/no),
Charlson Co-morbidity Index (CCI) and mental health conditions. A proxy measure for disease
severity was created by identifying recipients in our sample who had acute care service
utilization (hospitalization or ER visit) wherein the primary diagnosis was listed as autism.
Disease severity was further categorized as ‘yes’ or ‘no’ based on whether a recipient with
autism had a hospitalization/ER visit with a primary diagnosis of autism or not. The comorbidity profile of recipients was calculated by using Deyo modification of CCI (Deyo,
Cherkin, & Ciol, 1992). A proxy for other mental health conditions was also created for the
following conditions: schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), bipolar
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disorder, depression, anxiety and mental retardation. Co-morbid measures were assessed using
data for calendar year 2006.
Other demographic variables
Age was computed as of December 31st of each year (2006-2008) in order to determine
eligibility for inclusion each year. Age, race/ethnicity, gender, location of residence and
geographical region stratification was also used in the analysis. Age was categorized into five
groups: 18-24 years, 25-35 years, 36-45 years, 46-55 years and 56-64 years. Race was
categorized as white, black, and others (consisting of more than one race and unknown race).
Location of residence was classified as urban and rural based on Rural Urban Commuting Area
(RUCA) codes (RUCA Data, 2013).
Analysis
Means and standard deviation or frequency and percentages were used to describe the
characteristics of the study recipients, as appropriate. All analyses were conducted using
Statistical Analysis Software (SAS) version 9.3 (SAS Institute Inc, Cary, NC).
Trends in prevalence and medical services utilization
Logistic regression was modeled to assess trends from 2006 to 2008 in the proportion of adults
with autism (prevalence) with year as a predictor variable. The proportion of recipients (N/%)
using medical services (outpatient visits, inpatient visits and ER visits) stratified by demographic
variable were also reported. The mean medical services utilization was also reported for each
year individually.
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Trends in prescription drug utilization
The number of users, average prescription (mean with standard deviation) was reported for all
the individual classes for 2006, 2007 and 2008 separately. The individual classes included in
this study were antipsychotics, antidepressants, stimulants, anxiolytics/hypnotics/sedatives and
other psychotropics. Information on any prescriptions as well as for any psychotropic drug use
was also provided for all three years.
Predictors of healthcare utilization and costs
Bivariate analysis between all-cause outpatient visits, inpatient visits, ER visits and total
expenditures with study characteristics was conducted using Wilcoxon-Mann-Whitney test or
Kruskal Wallis test, as appropriate. In order to determine the predictors of all-cause outpatient,
inpatient and ER visits and the total all-cause cost among adults with autism, the following
analyses were conducted. Generalized linear mixed model (GLMM) with an appropriate
distribution and log link was modeled. For appropriate distribution (Gaussian, Poisson, Gamma,
and Inverse Gaussian) for GLMM, Modified Park test was conducted. GLMM models account
for the correlation at different levels. There is a clustering effect at the state level. Using
ordinary regression without accounting for clustering can lead to biased standard error estimates.
Therefore, a two level model with patient at the first-level and states at the second-level was
modeled. All the models were computed with age, race/ethnicity, gender and location of
residence as predictor variables. Fee-for-service, CCI, mental health disorders and disease
severity were added as confounders. Poisson distribution with log link was found to be the most
appropriate for all the models based on Modified Park test. Results were reported using incident
rate ratios. Total healthcare utilization and cost was calculated by summing all the visits or cost
reimbursed by Medicaid for calendar years 2007-2008. The demographic and co-morbid
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variables were calculated for year 2006. The multilevel analysis was conducted by using PROC
GLIMMIX procedure in SAS version 9.3 (SAS Institute Inc, Cary, NC).
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RESULTS
Prevalence rates
The prevalence rates were 2.66 per 1,000 in 2006, 3.25 per 1,000 in 2007 and 3.66 per 1,000
Medicaid beneficiaries in 2008 (Table 1). Based on the logistic regression results, the prevalence
of autism among adults increased significantly from 2006 to 2008 (p<0.001). Across all years,
prevalence rates were higher among adults aged 18-25 years (5.8/1000 in 2006, 7.1/1000 in 2007
and 8.2/1000 in 2008), males (6.8/1000 in 2006, 8.2/1000 in 2007 and 9.2/1000 in 2008) and
whites (3.8/1000 in 2006, 4.5/1000 in 2007 and 5.1/1000 in 2008). The prevalence rates by the
location of residence (urban vs. rural) remained stable for all three years.

116

117

Table 4.1: Prevalence rates (per 1000) by demographic variables
2006
2007
2008
Rates
Rates
N (%)
N (%)
N (%)
/1000
/1000
Autism cases
19183
2.658
24160
3.245
29745
(Prevalence)*
Age group
13188 (68.75)
5.838
16625 (68.81)
7.149
20692 (69.59)
18-25 years
4212 (21.96)
2.303
5270 (51.81)
2.831
6373 (21.43)
26-35 years
1110 (5.79)
0.842
1410 (5.84)
1.077
1631 (5.48)
36-45 years
673 (3.51)
0.371
855 (3.54)
0.439
1049 (3.53)
46-65 years
Gender
13997 (72.97)
6.828
17703 (73.27)
8.207
21949 (73.79)
Male
5186 (27.03)
1.003
6457 (26.73)
1.221
7796 (26.21)
Female
Race
10898 (56.81)
3.749
13717 (56.78)
4.546
16793 (56.46)
White
4520 (23.56)
2.394
5610 (23.22)
2.91
6514 (21.9)
Black or AA
1254 (6.54)
1.013
1568 (6.49)
1.224
2064 (6.94)
Hispanic
2511 (13.09)
2.118
3265 (13.53)
2.68
4374 (14.71)
Other
Location of residenceϯ
15799 (83.99)
2.651
19911 (83.96)
3.241
24497 (83.98)
Urban
3012 (16.01)
2.608
3803 (16.04)
3.194
4674 (16.02)
Rural
Rates are expressed per total Medicaid Population in that year
*Trends in prevalence is significant based on logistic regression with year as a predictor variable
ϯ
Based on 2013 Rural Urban Commuting Area codes

Rates
/1000
3.659

Percent
Change from
2006 vs. 2008
38%

8.198
3.089
1.167
0.489

40%
34%
39%
32%

9.222
1.356

35%
35%

5.086
3.112
1.48
3.265

36%
30%
46%
54%

3.654
3.561

38%
37%

Trends in medical services users and utilization
Rates per 10,000 Medicaid patients were reported for outpatient, inpatient and ER cases (Table
2). The proportion of adults with autism having outpatient, inpatient and ER room visits were
higher for age group 18-25 years, males and whites. On average, there were ~37 outpatient visits
in 2006, ~35 outpatient visits in 2007 and ~36 outpatient visits in 2008 (Table 3). For all three
years, adults with autism had ~1 inpatient visit per year (1.21 [±1.99] in 2006, 1.28 [±2.05] in
2007 and 1.34 [±2.03] in 2008) and ~3 ER room visits (2.52 [±3.54] in 2006, 2.54 [±3.49] in
2007 and 2.60 [±3.71] in 2008) per year.

118

119

Table 4.2: Medical services user rates (per 10,000) over three year period (2006-2008)
Outpatient visits cases Inpatient visits cases Emergency room visits cases
2006
2007
2008 2006 2007 2008
2006
2007
2008
25.84 31.40 35.35 1.73
2.1
2.27
7.17
8.92
10.22
Total
Age group
56.55
68.8
78.76 3.24 3.78 4.37
14.71
18.24
21.59
18-25 years
22.52 27.62 30.11 1.65 2.15 2.03
6.58
8.17
8.98
26-35 years
8.31
10.62 11.49 0.93 1.19 1.14
2.83
3.82
4.04
36-45 years
3.67
4.35
4.85
0.5
0.67 0.76
1.5
1.93
2.06
46-65 years
Gender
66.25 79.27 88.94 3.86 4.59 30.13
17.48
21.63
24.75
Male
9.82
11.88 13.17 0.88 1.09 1.09
3.08
3.73
4.21
Female
Race
36.46 43.96
49.1
2.33 2.82 2.92
10.54
12.57
14.00
White
23.53 28.44 30.43 1.52 1.83 2.22
6.37
8.34
9.49
Black or AA
9.74
11.81 14.14 0.78 0.94 0.97
2.97
3.61
4.24
Hispanic
20.3
25.62 31.22 1.58 1.98 2.09
4.55
6.35
8.26
Other
Location of residenceϯ
25.7
31.23 35.15 1.70 2.09 2.32
7.01
8.79
10.12
Urban
25.69 31.46 35.09 1.77 1.97 1.86
7.63
9.25
10.19
Rural
18,655 23,379 28,738 1,248 1,566 1,844
5,173
6,638
8,309
Total Cases, N
Rates are expressed per total Medicaid Population in that year
ϯ
Based on 2013 Rural Urban Commuting Area codes

Table 4.3: Total medical service utilization by type of service for individual years
2006
2007
2008
36.86 (55.89) 34.96 (53.17) 35.98 (56.38)
Average outpatient visits, Mean (SD)
1.21 (1.99)
1.28 (2.05)
1.34 (2.03)
Average inpatient visits, Mean (SD)
2.54 (3.49)
2.60 (3.71)
Average emergency room visits, Mean (SD) 2.52 (3.54)

Trends in prescription drug utilization
The total number of recipients taking any psychotropic drug as well as the average number of
any psychotropic prescriptions increased slightly over the three years (Table 4; N; Mean[SD]14,802; 27.30 [±20.35] in 2006, 18,465; 27.51 [±20.71] in 2007 and 22,662; 27.74 [±21.11] in
2008). The total number of recipients taking antipsychotics, antidepressants, CNS stimulus,
anxiolytics/sedatives/hypnotics and other psychotropics also increased from 2006 to 2008 (Table
4). Antipsychotic drugs (10,297 in 2006; 12,922 in 2007; 15,730 in 2008) had the highest
number of users followed by antidepressants (7,517 in 2006; 9,344 in 2007; 11,447 in 2008) and
anxiolytics/sedatives/hypnotics (2,458 in 2006; 3,184 in 2007; 3,702 in 2008) among adults with
autism for all three years.
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Table 4.4: Prescription drug use by individual classes for individual years
2006
Average any prescription fills, N; Mean (SD)
17,068; 41.13 (35.46)
Average any psychotropic fills, N; Mean (SD)
14,801; 27.30 (20.35)
10,297; 14.07 (9.70)
Average antipsychotic drug fills, N; Mean (SD)
7,517; 10.61 (6.45)
Average antidepressants drug fills, N; Mean (SD)
2,039; 9.45 (6.11)
Average CNS stimulus drug fills, Mean (SD)
Average Anxiolytic/sedatives/hypnotics drug fills, Mean
2,458; 6.50 (5.56)
(SD)
9,339;
15.45 (11.97)
Average Other psychotropic drug fills, Mean (SD)
CNS, Central nervous systems.
N = Total number of people taking medications

2007
21,449; 41.05 (36.08)
18,465; 27.51 (20.71)
12,922; 14.24 (9.95)
9,344; 10.44 (6.47)
2,758; 9.62 (6.37)

2008
26,355; 41.69 (36.85)
22,662; 27.74 (21.11)
15,730; 14.38(10.28)
11,447; 10.48 (6.51)
3,679; 9.60 (6.20)

3,184; 6.59 (5.49)
11,576; 15.46 (12.14)

3,702; 6.79 (5.75)
14,194; 15.64 (12.37)
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Predictors of healthcare utilization and cost
Bivariate analysis
Wilcoxon-Mann-Whitney test or Kruskal Wallis test analyses showed that the all-cause medical
utilization (Table 5) and total cost (Table 6) varied by different demographic variables and comorbid factors. Utilization and cost were added for calendar years 2007 and 2008.
Demographic variables were calculated for year 2006. For outpatient visits, all the variables
were found to be significant where adults aged 46-65 years (97.73 [±131.46]), females (76.17
[±108.90]), white (77.56 [±122.85]) and urban location (73.02 [±107.36]) had higher outpatient
visits (p<0.001). Recipients with higher disease severity (96.32 [±112.69] vs. 73.03 [±107.93];
p<0.001) and co-morbid mental conditions (84.97 [±111.86] vs. 70.68 [±106.93]; p<0.001) had
significantly higher outpatient visits. Race and disease severity were found to be significantly
associated with inpatient visits (p<0.05). ER visits also significantly differed based on the age
groups, race and disease severity (p<0.05). Lastly, all-cause total cost significantly differed
among all the demographic variables (except gender) and co-morbid conditions (p<0.001).
Adults who were aged 26-35 years ($133,052.01 [±$105,488.28]), had white ethnicity
($111,628.27 [±$98,714.51]), and were located in urban location ($158,870.01 [±$148,569.59])
had higher all-cause healthcare costs for calendar years 2007-08.
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Table 4.5: Differences in medical service utilization by study characteristics
Outpatient visits
Inpatient visits
Median
P
Median
Mean (SD)
Mean (SD)
(Range)
value
(Range)
<0.001
Age group
69.45 (103.48)
33 (0–731)
0.08 (0.53) 0 (0–15)
18-25 years
82.53 (118.19)
37 (0–731)
0.08 (0.45)
0 (0–8)
26-35 years
80.60 (108.47)
37 (0–541)
0.09 (0.51)
0 (0–7)
36-45 years
97.73 (131.46)
47 (0–608)
0.08 (0.44)
0 (0–5)
46-65 years
0.0019
Gender
72.78 (107.84)
34 (0–731)
0.08 (0.51) 0 (0–15)
Male
76.17 (108.90)
37 (0–731)
0.09 (0.51) 0 (0–12)
Female
<0.001
Race
77.56 (122.85)
29 (0–731)
0.07 (0.42)
0 (0–5)
White
66.95 (96.89)
33 (0–731)
0.09 (0.68) 0 (0–15)
Black
74.80 (106.92)
37 (0–731)
0.08 (0.46) 0 (0–12)
Other
Location of
<0.001
residenceϯ
73.02 (107.36)
34 (0–731)
0.08 (0.54) 0 (0–15)
Urban
71.51 (102.51)
37 (0–731)
0.07 (0.34)
0 (0–4)
Rural
123.37 (190.34)
37 (0–731)
0.06 (0.29)
0 (0–2)
Unknown
<0.001
Insurance
79.31 (103.14)
29 (0–731)
0.08 (0.51) 0 (0–15)
Managed care
69.42 (111.41)
44 (0–731)
0.08 (0.52) 0 (0–12)
Fee-for service
<0.001
Disease severity
96.32 (112.96) 52.5 (5–608)
0.55 (1.28)
0 (0–8)
Yes
73.03 (107.93)
34 (0–731)
0.07 (0.47) 0 (0–15)
No
Co-morbid
<0.001
mental conditions
84.97 (111.86)
46 (0–731)
0.06 (0.35)
0 (0–5)
Yes

Emergency room visits
P
Median
P
Mean (SD)
value
(Range)
value
0.819
0.0025
0.99 (2.77) 0 (0–87)
1.05 (2.60) 0 (0–52)
0.95 (2.00) 0 (0–22)
1.14 (2.23) 0 (0–18)
0.1084
0.7109
0.99 (2.61) 0 (0–87)
1.05 (2.92) 0 (0–71)
0.0336
0.0105
0.89 (2.89) 0 (0–87)
0.90 (1.99) 0 (0–22)
1.08 (2.84) 0 (0–71)
0.3012

0.1378
1.00 (2.76)
1.03 (2.36)
0.86 (1.67)

0 (0–87)
0 (0–30)
0 (0–9)

0.3751

0.2336
1.05 (2.96)
0.97 (2.47)

0 (0–71)
0 (0–87)

<0.001

<0.001
3.80 (7.19)
0.94 (2.43)

2 (0–87)
0 (0–71)

0.3012

0.1411
1.00 (2.41)

0 (0–33)

70.68 (106.93)
32 (0–731)
0.09 (0.55) 0 (0–15)
No
P values were calculated based on Wilcoxon-Mann-Whitney test or Kruskal Wallis test.
ϯ
Based on 2013 Rural Urban Commuting Area codes

1.01 (2.75)

0 (0–87)

124

125

Table 4.6: Differences in healthcare expenditure by study characteristics
N (%)
Mean (SD)
Median (Range)
Age group
6,415 (70.16)
$95,035 ($89,412)
$65,572 ($74 – $763,593)
18-25 years
2,082 (22.77) $133,052 ($105,488) $112,090 ($158 – $659,848)
26-35 years
447 (4.89)
$130,285 ($108,547) $110,698 ($241 – $579,157)
36-45 years
199 (2.18)
$129,365 ($112,383) $98,341 ($2,511 – $581,251)
46-65 years
Gender
6,960 (76.12)
$106,104 ($96,848)
$75,701 ($74 – $763,593)
Male
2,183 (23.88)
$106,351 ($94,737)
$79,312 ($158 – $679,358)
Female
Race
1,732 (18.94)
$111,628 ($98,715)
$83,064 ($74 – $699,309)
White
2,015 (22.04)
$92,648 ($89,529)
$63,973 ($125 – $763,593)
Black
5,396 (59.02)
$104,859 ($94,961) $71,507.50 ($198 – $588,610)
Other
Location of residence
7,513 (82.17) $158,870 ($148,570) $118,604 ($1,355 – $659,848)
Urban
1,481 (16.20)
$107,145 ($95,337)
$77,534 ($125 – $763,593)
Rural
149 (1.63)
$95,879 ($92,759)
$69,406 ($74 – $667,304)
Unknown
Insurance
5,285 (57.80)
$84,606 ($81,514)
$52,838 ($74 – $699,309)
Managed care
3,858 (42.20) $135,693 ($106,718) $113,437 ($168 – $763,593)
Fee-for service
Disease severity
220 (2.41)
$141,989 ($120,436) $119,689 ($2,343 – $763,593)
Yes
8,923
(97.59)
$105,280 ($95,511)
$75,805 ($74 – $699,309)
No
Co-morbid mental conditions
1,861 (20.35)
$129,434 ($97,890)
$111,494 ($389 – $657,388)
Yes
7,282 (79.65)
$100,216 ($95,041)
$67,678 ($74 – $763,593)
No
9,143 (100.00) $106,163 ($96343)
$76,675 ($74 – $763,593)
Total
P values were calculated based on Wilcoxon-Mann-Whitney test or Kruskal Wallis test.
ϯ
Based on 2013 Rural Urban Commuting Area codes

Inter-quartile range

P value
<0.001

$28,021 – $134,723
$49,931 – $194,357
$47,068 – $181,914
$34,965 – $200,559
0.3061
$31,268 – $155,113
$34,159 – $153,342
<0.001
$34,927 – $164,168
$26,224 – $133,315
$34,723 – $142,839
<0.001
$51,780 – $203,861
$33,933 – $155,833
$23,561 – $144,399
<0.001
$25,187 – $123,877
$51,934 – $198,058
<0.001
$51,780 – $194,127
$31,704 – $153,993
<0.001
$51,780 – $177,567
$28,014 – $145,319
$31,982 – $154,786

GLMM results
GLMM was modeled to study the predictors of outpatient visits (Table 7), inpatient visits (Table
8), ER visits (Table 9) and healthcare expenditure (Table 10). Based on the GLMM results, age
group 18-25 years had significantly lower outpatient visits by a factor of 0.773 compared to
adults aged 46-65 years (IRR = 0.773; p<0.01) after controlling for other variables and statelevel effect. Significantly lower outpatient visits were found among whites compared to blacks
(IRR = 0.909; p=0.001) after controlling for other variables. Adults with autism residing in
urban areas had ~1.6 times higher outpatient visits compared to those in rural areas (IRR =
1.641; p<0.001). None of the demographic variables were found to be significant in the GLMM
analyses for inpatient visits. Only race was found to be a significant predictor of ER visits;
where, after controlling for all the variables, whites had lower ER visits then blacks (IRR=0.889;
p<0.04) and others (IRR=0.848; p=0.01). For all-cause expenditure, all variables were found to
be significant predictors among adults with autism. Adults with autism aged 18-25 years (IRR =
0.82; p<0.001) had lower total cost, while adults aged 26-35 years (IRR = 1.084; p<0.001) and
36-45 years (IRR = 1.055; p<0.001) had higher total cost than those aged 46-55 years. Overall,
higher expenditures were found for males compared to females (IRR = 1.024; p<0.01), whites
compared to blacks (IRR = 1.084; p<0.01), and adults located in urban areas compared to rural
areas (IRR = 1.415; p<0.01).
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Table 4.7: Predictors of outpatient visits
Variables
Coefficient (SE)
IRR
95% CI
P value
Age groups in years
-0.258 (0.075)
0.773
-0.404 – -0.111
0.001
18-25 vs. 46-65
-0.146
(0.077)
0.864
-0.296
–
0.004
0.056
26-35 vs. 46-65
-0.146
(0.087)
0.864
-0.317
–
0.025
0.095
36-45 vs. 46-65
-0.045 (0.025)
0.956
-0.094 – 0.004
0.073
Male vs. Female
Race
-0.095 (0.029)
0.909
-0.152 – -0.039
0.001
White vs. Black
0.028 (0.032)
1.028
-0.034 – 0.089
0.381
White vs. Other
Location of residence
0.496 (0.099)
1.641
0.302 – 0.689
<0.0001
Urban vs. Rural
0.023
(0.031)
1.023
-0.039
–
0.084
0.467
Unknown vs. Rural
-0.164
(0.040)
0.849
-0.242
–
-0.086
<0.0001
Managed care vs. FFS
0.149 (0.028)
1.161
0.094 – 0.204
<0.0001
Co-morbid Mental Conditions–Y/N
0.265 (0.070)
1.303
0.127 – 0.402
0.000
Disease severity –Y/N
Ϯ
0.163 (0.014)
1.178
0.135 – 0.192
<0.0001
Other comorbid conditions
IRR, incident rate ratio; FFS, fee-for-service; CI, confidence interval
P values were calculated based on Generalized Linear Mixed Model (Poisson regression)
ϯ
Based on 2013 Rural Urban Commuting Area codes
Ϯ
Based on Deyo et al., 1996
Demographic variables, comorbid conditions and disease severity were calculated for year 2006.
Total healthcare utilization variables were calculated by summing all the visits in calendar years 2007-2008.
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Table 4.8: Predictors of inpatient visits
Variables
Coefficient (SE)
IRR
95% CI
P value
Age groups in years
0.105 (0.379)
1.111
-0.638 – 0.848
0.782
18-25 vs. 46-65
0.014
(0.389)
1.014
-0.749
–
0.777
0.972
26-35 vs. 46-65
-0.372
(0.460)
0.689
-1.274
–
0.530
0.419
36-45 vs. 46-65
-0.088 (0.131)
0.916
-0.344 – 0.168
0.500
Male vs. Female
Race
-0.220 (0.153)
0.803
-0.519 – 0.079
0.150
White vs. Black
-0.060 (0.170)
0.942
-0.393 – 0.274
0.726
White vs. Other
Location of residence
0.020 (0.535)
1.020
-1.030 – 1.069
0.971
Urban vs. Rural
0.003
(0.165)
1.003
-0.321
–
0.327
0.986
Unknown vs. Rural
0.078
(0.182)
1.081
-0.279
–
0.435
0.670
Managed care vs. FFS
-0.102 (0.156)
0.903
-0.409 – 0.204
0.514
Co-morbid Mental Conditions–Y/N
1.842 (0.265)
6.307
1.323 – 2.361
<0.0001
Disease severity –Y/N
Ϯ
0.329 (0.063)
1.389
0.205 – 0.452
<0.0001
Other co-morbid conditions
IRR, incident rate ratio; FFS, fee-for-service; CI, confidence interval
P values were calculated based on Generalized Linear Mixed Model (Poisson regression)
ϯ
Based on 2013 Rural Urban Commuting Area codes
Ϯ
Based on Deyo et al., 1996
Demographic variables, comorbid conditions and disease severity were calculated for year 2006.
Total healthcare utilization variables were calculated by summing all the visits in calendar years 2007-2008.
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Table 4.9: Predictors of emergency room visits
Variables
Coefficient (SE)
IRR
95% CI
P value
Age groups in years
0.045 (0.150)
1.047
-0.249 – 0.340
0.762
18-25 vs. 46-65
0.072
(0.154)
1.074
-0.230
–
0.373
0.642
26-35 vs. 46-65
-0.042
(0.178)
0.959
-0.391
–
0.307
0.814
36-45 vs. 46-65
0.000 (0.052)
1.000
-0.101 – 0.101
0.999
Male vs. Female
Race
-0.117 (0.058)
0.889
-0.231 – -0.003
0.044
White vs. Black
-0.165 (0.064)
0.848
-0.291 – -0.039
0.010
White vs. Other
Location of residence
-0.270 (0.196)
0.763
-0.653 – 0.113
0.167
Urban vs. Rural
-0.041
(0.063)
0.960
-0.164
–
0.082
0.515
Unknown vs. Rural
-0.002
(0.069)
0.998
-0.137
–
0.133
0.976
Managed care vs. FFS
0.046 (0.056)
1.047
-0.065 – 0.157
0.414
Co-morbid Mental Conditions–Y/N
1.274 (0.131)
3.573
1.018 – 1.529
<0.0001
Disease severity –Y/N
Ϯ
0.291 (0.028)
1.338
0.236 – 0.347
<0.0001
Other co-morbid conditions
IRR, incident rate ratio; FFS, fee-for-service; CI, confidence interval
P values were calculated based on Generalized Linear Mixed Model (Poisson regression)
ϯ
Based on 2013 Rural Urban Commuting Area codes
Ϯ
Based on Deyo et al., 1996
Demographic variables, comorbid conditions and disease severity were calculated for year 2006.
Total healthcare utilization variables were calculated by summing all the visits in calendar years 2007-2008.
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Table 4.10: Predictors of total health care expenditure
Variables
Coefficient (SE)
IRR
95% CI
P value
Age groups in years
-0.198 (0.0002)
0.820
-0.199 – -0.198
<0.0001
18-25 vs. 46-65
0.081 (0.0002)
1.084
0.080 – 0.081
<0.0001
26-35 vs. 46-65
0.053 (0.0002)
1.055
0.053 – 0.054
<0.0001
36-45 vs. 46-65
0.024 (0.0001)
1.024
0.023 – 0.024
<0.0001
Male vs. Female
Race
0.081 (0.0001)
1.084
0.081 – 0.081
<0.0001
White vs. Black
0.182
(0.0001)
1.199
0.182
–
0.182
<0.0001
White vs. Other
Location of residence
0.347 (0.0003)
1.415
0.347 – 0.348
<0.0001
Urban vs. Rural
0.106 (0.0001)
1.111
0.106 – 0.106
<0.0001
Unknown vs. Rural
-0.453 (0.0001)
0.636
-0.453 – -0.453
<0.0001
Managed care vs. FFS
0.226 (0.0001)
1.254
0.226 – 0.227
<0.0001
Co-morbid Mental Conditions–Y/N
0.267 (0.0002)
1.307
0.267 – 0.268
<0.0001
Disease severity –Y/N
Ϯ
0.073
(0.0001)
1.076
0.073
–
0.073
<0.0001
Other co-morbid conditions
IRR, incident rate ratio; FFS, fee-for-service
P values were calculated based on Generalized Linear Mixed Model (Poisson regression)
ϯ
Based on 2013 Rural Urban Commuting Area codes
Ϯ
Based on Deyo et al., 1996
Demographic variables, comorbid conditions and disease severity were calculated for year 2006.
Total healthcare cost was calculated by summing all the costs reimbursed by Medicaid in calendar years 2007-2008

DISCUSSION
To the best of our knowledge, this is the first study to report prevalence rates, all-cause medical
utilization, prescription use and all-cause expenditure among adults with autism using multi-state
Medicaid claims data. A total of 19,183 adults in 2006, 24,160 adults in 2007 and 29,745 adults
in 2008 had autism across 39 state Medicaid programs. The prevalence rate of autism was 2.7
per 1,000 in 2006, 3.3 per 1000 in 2007 and 3.7 per 1,000 among Medicaid beneficiaries in 2008.
This is considerably lower than 1% prevalence rates among adults in England (Brugha, et al.,
2011). The lower rates may be attributed to the nature of our sample and insurance system in the
US. Not all adults with autism in the US will be enrolled in Medicaid program. It is likely that
adults with autism have other private insurance or no insurance to cover their needed care and
treatment. Since we identified adults with autism based on medical services utilization, those
adults with autism enrolled in Medicaid who did not have a claim for study year would have
been excluded from our calculation. A study by Shimabukuro et al. (2007) reported
administrative autism prevalence of 1.2/1000 in 2003 among privately insured adults aged 18-24
years. This is lower than what we found in our sample. With the increasing prevalence of
autism among children, it is expected that prevalence rates for adults will rise, which may
explain the higher prevalence rates observed in our study as compared to those reported by
Shimabukuro et al. (2007).
Our study results illustrate a significant increase of 38% in the prevalence rate from 2006
to 2008. Only one study so far has reported trends in prevalence among adults, where the adult
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cases with autism were reported to increase by 121.4% from 2002 to 2006 in vocational
rehabilitation (VR) programs in the US (Cimera & Cowan, 2009). The increasing prevalence of
autism among children may explain the trends observed among adults in this study. Similar to
the general demographics distribution among individuals with autism (Boyle et al., 2011;
Brugha, et al., 2011; Mandell et al., 2009), we also found higher prevalence rates among white
and male adults with autism. In our study, males were ~7 times more likely (prevalence rate) to
have a diagnosis of autism compared to females across all age groups. In addition, we also
found higher prevalence rate among younger adults aged 18-25 years compared to other age
groups. Autism is more common among children than adults (Buescher, et al., 2014; Cidav,
Lawer, Marcus, & Mandell, 2012). Therefore, it is possible that with more people transitioning
from childhood to adulthood, we see higher prevalence rate among younger adults.
Information on health care utilization and expenditure among adults with autism is
currently limited in the US. Adults with autism on average had ~36 outpatient visits, ~1
inpatient visit and ~3 ER visits during a year. From 2006 to 2008, we found an increase in
outpatient visits (36.8%), ER visits (42.25%) and prescription claims (35.56%). Similar to
prevalence rates, higher medical services users were young adults (18-25 years), males and
whites. As autism prevalence increases, there is likely to be an increase in healthcare burden
associated with this disorder. State policy makers should consider the rising medical resource
use and costs of autism in making Medicaid budget allocation decisions.
In spite of higher medical services usage among young adults, outpatient visits were
significantly higher among older adults after controlling for other demographic and co-morbid
conditions. This could be related to gradual progression in age leading to higher office-related
visits in this population. In this study, we created three proxy variables to control for co-morbid
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conditions, including a proxy variable for common mental co-morbid conditions such as
schizophrenia, ADHD, bipolar disorder, depression, anxiety and mental retardation in this
population. However, it is also possible that older adults have other co-morbid conditions,
contributing to higher outpatient visits. For example, adults with autism are more likely to have
co-morbid conditions such as intellectual disability, bowels disorder, epilepsy, autoimmune
disease, sleep disorder, and others (Buck, et al., 2014; Kohane et al., 2012) compared to children
with autism. Therefore, general progression of age as well as occurrence of co-morbid
conditions may lead to higher outpatient visits among older adults. Though prevalence rates
were higher among whites, black adults had significantly higher outpatient visits and ER visits.
Racial differences have been reported among children with autism with black children having a
delayed diagnosis and being less likely to receive early treatment and intervention than white
children (Mandell, Listerud, Levy, & Pinto-Martin, 2002; Mandell, et al., 2009). This delay in
diagnosis and treatment provision early in childhood may eventually translate to higher resource
use as they transition to adulthood. It is also documented that black children have difficulties in
receiving quality healthcare compared to white children with autism (Magana, Parish, Rose,
Timberlake, & Swaine, 2012). Adults with autism located in urban locations compared to rural
locations had higher outpatient visits. Better access to support services and resources in urban
locations (compared to rural locations) could have contributed to the higher visits observed
among adults located in those areas.
The average all-cause expenditure among adults with autism was around $106,163 over
the two-year period. The total cost was significantly higher among older adults with autism
compared to the other age groups. This finding is consistent with Cidav et al. (2012), where the
authors reported an increase in expenditure with age among Medicaid recipients with autism.
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Males had higher expenditures compared to females. Contrary to resource utilization (outpatient
visits and ER visits), higher expenditure was found among whites compared to blacks. Adults
with autism in urban locations had higher average expenditure than those in rural locations.
Variation in disease severity, treatment intensity, and availability of resources may explain these
differences. Further research is needed to fully understand the underlying reasons contributing to
cost differential among adults with autism.
Similar to the studies in the past, we also found substantial psychotropic drug use among
adults with autism. Three-fourths of adults (77.2% in 2006, 76.4% in 2007 and 76.2% in 2008)
with autism were taking some type of psychotropic medication to manage their symptoms. The
proportion of adults using psychotropic medication found in our study is higher than previous
studies in adults (~60% [Khanna et al., 2013]) as well as children (~40% [Logan et al., 2012];
56% [Mandell et al., 2008]; ~67% [Khanna et al., 2013]) with autism enrolled in the Medicaid
program. Similar to other studies, we also found that majority of the adults to have been
prescribed antipsychotics or/and antidepressants (Esbensen, et al., 2009; Khanna, et al., 2013;
Logan, et al., 2012). Despite their underlying side-effect profile, antipsychotics are commonly
prescribed among individuals with autism. With such high usage of antipsychotics, policy
makers, providers, and caregivers of adults with autism should consider if the benefit of
prescribing these drugs outweigh their risks. The average prescription for any psychotropic drug
was close to 28 scripts (27.3 in 2006; 27.5 in 2007 and 27.7 in 2008), which is almost similar to
an average of 29 scripts reported by Khanna et al. (2013) in Mississippi Medicaid population.
Limitations
The study has a few limitations. The identification of autism cases was based on diagnostic
codes (ICD-9-CM). Misclassification or coding errors during claims processing could affect
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study results. We could not estimate specific autism-related costs in this study. The all-cause
medical services utilization and costs reported in this study may not reflect the true healthcare
burden of autism, and may have led to an overestimation of our utilization and cost numbers.
Medicaid coverage varies by state, which may have affected the results of this study. However,
to account for this variation, we did add second-level (random effect) of state in the multilevel
modeling analysis to account for this variation. Yet other differential factors could exist that
were not addressed.
Conclusions
This is the first study to evaluate the trends in prevalence, health care utilization and predictors
of health care use and costs among adults with autism enrolled across several state Medicaid
programs. The results of this study demonstrated significant increase in the prevalence rate
among Medicaid adults with autism over the three-year study period. We also observed an
increase in medical services utilization in terms of outpatient visits, ER visits and inpatient visits
from 2006 to 2008. Our results also suggest significant variation in outpatient visits, ER visits
and total expenditure between different demographic variables. With rising autism prevalence,
state Medicaid programs need to consider the resource impact of this rising trend, and make
appropriate budgetary decisions to address the needs of this growing population.
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CHAPTER 5
SUMMARY AND FUTURE RESEARCH
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STUDY SUMMARY
Over the last several years, the prevalence of developmental disabilities, particularly autism has
significantly increased among children (Boyle et al., 2011). Recent estimates suggest that 1 in
68 children have autism in the Unites States (US) (MMWR, 2014). With rising prevalence
among children, it is likely that similar trends will be observed among adults as these children
transition to adulthood. However, few studies so far have focused on health outcomes among
adults with autism. By using both primary and secondary data collection techniques, this
dissertation bridges the gap in the literature by providing information on quality of life (QOL),
prevalence rate and healthcare utilization and costs among adults with autism.
The psychometric properties of a generic QOL measure, i.e., WHOQOL-BREF were
tested in this study (Specific Aim 1). Using such an instrument in autism may provide us
insights into the thoughts and perspectives of a population for which much remains unknown.
However, before WHOQOL-BREF can be used routinely among adults with autism, it is
essential that we assess its psychometric profile in this population. Study findings demonstrated
adequate support for the convergent validity, discriminant validity, and reliability and partial
support for the known-groups validity of WHOQOL-BREF among adults with autism. We
failed to find any significant differences between low and high autism severity groups for social
relationships and environmental domains.
This is the first study to assess QOL and its predictors among adults with autism in the
US (Specific Aim 2). By using a modified Wilson and Cleary’s model, the results from this
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dissertation successfully provide details on individual QOL domains (physical,
psychological, social relationships and environmental) and identify potential areas for
improvement in adults with autism. The role of social support, functional independence, autism
severity and coping and its relationship with QOL was established using structural equation
modeling (SEM) and hierarchical linear regression analyses techniques. The study results
suggest significant direct (negative) and indirect (positive) impact through coping, social support
and functional independence on QOL. Significant negative outcomes of maladaptive coping on
QOL were observed in this study. QOL was also found to be better among adults with higher
functional independence in terms of performing daily household tasks and other activities.
Perceived social support was found to be a significant positive predictor of QOL.
Using multi-state Medicaid data, trends in autism prevalence and healthcare utilization
and cost among adults with autism was determined (Specific Aim 3). From 2006 to 2008, we
found a 38 % significant increase in the prevalence rate among adults with autism where 3.6 per
1,000 Medicaid recipients had autism in 2008. Consistent with the epidemiological data among
children, higher prevalence was found among males and whites. Almost 76% of recipients were
taking some type of psychotropic drug in the study period. Majority of adults were taking
antipsychotics and antidepressants. The results of this dissertation suggest an urgent need of
developing appropriate medication use guidelines in this population. Significant demographic
variation in outpatient visits, ER visits and all-cause expenditures was observed among adults
with autism. Higher ER and outpatient visits were found among blacks compared to whites.
All-cause total expenditure was higher among older adults, males, and whites.
The results from this dissertation imply significant health outcome burden among adults
with autism. By establishing the psychometric profile of WHOQOL-BREF, this study provides
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providers and health care professionals involved in management of autism among adults with the
disorder a useful approach for the assessment of QOL among such individuals. By assessing the
QOL and its predictors among adults with autism, this study highlights the role played by
modifiable factors such as coping and social support in influencing the QOL, and the need to
incorporate such measures in autism treatment management decisions. By assessing the trends in
prevalence among adults with autism enrolled in Medicaid program, this study found that the
issue of rising autism prevalence is not restricted to children.
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DIRECTIONS FOR FUTURE RESEARCH
Different avenues can be taken to build on current research:
Study 1. Future researchers could conduct a longitudinal study to determine concurrent
validity, predictive validity and test-retest reliability of the WHOQOL-BREF instrument among
adults with autism. Additional items are warranted in order to capture the social relationship
domain among adults with autism. Researchers who intend to use this instrument among adults
with autism should revalidate the known-groups validity with additional items for the social
relationship domain.
Study 2. In our study, we had an overrepresentation of adults with Asperger’s syndrome.
Future studies should be conducted among a broader and more representative sample. In order to
demonstrate the causal relationships between the key predictor variables (autism severity,
coping, functional independence and social support) and QOL, a longitudinal study should be
designed. Future studies could also include other predictors of QOL.
Study 3. The current study utilized three years (2006-2008) of multi-state Medicaid data to
provide information on prevalence of autism, prescription drug use and predictors of healthcare
utilization and costs among adults with autism. Future studies could utilize private insurance
claims data to demonstrate if the trends observed in this study hold well in other payer
populations.
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